[{"Studiencode":"05208762","Studiencode_Anzeige":"20019013","Kurzbezeichnung":"SGNPDL1V-001","Studientitel":"A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors","Status":"active","Phase":"Phase I","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"PD-L1","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT05208762","EudraCT-Nr":"2021-003517-19","Sponsor":"Seagen Inc.","Studienbeginn":"2023-02-21 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05208762"},{"Studiencode":"06061094","Studiencode_Anzeige":"20019000","Kurzbezeichnung":"EVOLVE","Studientitel":"Randomisierte Studie für Ph+ ALL mit Ponatinib versus Imatinib, gefolgt von Blinatumomab und Chemotherapie versus Indikation für Stammzelltransplantation bei molekularer CR oder Blinatumomab gefolgt von Stammzelltransplantation mit unvollständigem Ansprechen","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"BCR::ABL1, Ph+","Histologischer Typ":"ALL","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Stefan Schwartz","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT06061094","EudraCT-Nr":"2022-000760-21","Sponsor":"University of Frankfurt  (University of Frankfurt)","Studienbeginn":"2024-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06061094"},{"Studiencode":"05549297","Studiencode_Anzeige":"20021629","Kurzbezeichnung":"IMCgp100-203","Studientitel":"Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)","Status":"active","Phase":"Phase II/III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"HLA-A","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"2nd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT05549297","EudraCT-Nr":"2022-502732-39-00","Sponsor":"Immunocore Ltd, United Kingdom","Studienbeginn":"2024-01-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05549297"},{"Studiencode":"06064877","Studiencode_Anzeige":"20023101","Kurzbezeichnung":"AV-299 Aveo","Studientitel":"A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of Ficlatuzumab in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (FIERCE-HN)","Status":"active","Phase":"Phase III","Organsystem":"Kopf-Hals","Organsystem_Alias":"Kopf-Hals","Molekulare Marker":"HPV16","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Konrad Klinghammer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06064877","EudraCT-Nr":"2023-505606-42","Sponsor":"AVEO Pharmaceuticals, Inc","Studienbeginn":"2024-11-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06064877"},{"Studiencode":"05695508","Studiencode_Anzeige":"20019996","Kurzbezeichnung":"GMMG-HD10/DSMM XX","Studientitel":"Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Teclistamab- und Talequetamab-basierten Kombinationstherapien bei Teilnehmern mit neu diagnostiziertem multiplem Myelom, die für eine Transplantation geeignet sind.","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":null,"Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Jan Krönke","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT05695508","EudraCT-Nr":"2022-001186-12","Sponsor":"University of Heidelberg","Studienbeginn":"2023-10-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05695508"},{"Studiencode":"06043817","Studiencode_Anzeige":"20022495","Kurzbezeichnung":"Scorpion STX 721-101","Studientitel":"First-In-Human Study of STX-721 In Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","Status":"active","Phase":"Phase I/II","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"EGFR, HER2","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"Keine","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Damian Rieke Lang","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT06043817","EudraCT-Nr":"2023-506759-51-00","Sponsor":"Scorpion Therapeutics, Inc.","Studienbeginn":"2024-04-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06043817"},{"Studiencode":"06697301","Studiencode_Anzeige":"20025232","Kurzbezeichnung":"EIK1001-006","Studientitel":"A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma","Status":"active","Phase":"Phase II/III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT06697301","EudraCT-Nr":"2024-512659-19-00","Sponsor":"Eikon Therapeutics","Studienbeginn":"2025-12-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06697301"},{"Studiencode":"05007132","Studiencode_Anzeige":"20015003","Kurzbezeichnung":"FIRE 8","Studientitel":"Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","Status":"active","Phase":"Phase II","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT05007132","EudraCT-Nr":"2019-004223-20","Sponsor":"Charité","Studienbeginn":"2021-08-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05007132"},{"Studiencode":"05304377","Studiencode_Anzeige":"20019350","Kurzbezeichnung":"ELVN-001","Studientitel":"A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia","Status":"active","Phase":"Phase Ib","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"BCR::ABL1, ABL1","Histologischer Typ":"CML","Therapiesetting":"Metastasiert, Erstdiagnose, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Philipp le Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":"'+49 30 450 513 132","ClinTrials.gov identifier":"NCT05304377","EudraCT-Nr":"2022-000052-11","Sponsor":"Enliven Therapeutics","Studienbeginn":"2023-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05304377"},{"Studiencode":"06472245","Studiencode_Anzeige":"20025301","Kurzbezeichnung":"Artemia","Studientitel":"A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"HLA-A","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06472245","EudraCT-Nr":"2023-509340-10-00","Sponsor":"OSE Immunotherapeutics","Studienbeginn":"2025-05-07 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06472245"},{"Studiencode":"04928846","Studiencode_Anzeige":"20022129","Kurzbezeichnung":"M18-868","Studientitel":"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"c-MET","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT04928846","EudraCT-Nr":"2021-001811-94","Sponsor":"AbbVie","Studienbeginn":"2024-01-16 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04928846"},{"Studiencode":"05197192","Studiencode_Anzeige":"20019045","Kurzbezeichnung":"CLL16-Studie","Studientitel":"Eine prospektive, offene, multizentrische, randomisierte Phase-3-Studie mit Acalabrutinib, Obinutuzumab und Venetoclax (GAVE) im Vergleich zu Obinutuzumab und Venetoclax (GVE) bei zuvor unbehandelten Patienten mit Hochrisiko (17p-Deletion, TP53-Mutation oder komplexem Karyotyp) chronischer lymphatischer Leukämie (CLL).","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"17p-Deletion, komplexer Karyotyp, TP53","Histologischer Typ":"CLL","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Frederik Damm","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT05197192","EudraCT-Nr":"2020-004360-26","Sponsor":"Deutsche CLL Studiengruppe (DCLLSG)","Studienbeginn":"2023-08-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05197192"},{"Studiencode":"06162221","Studiencode_Anzeige":"20023275","Kurzbezeichnung":"RMC-LUNG-101","Studientitel":"Eine Plattform-Studie zur Therapie mit Kombinationen aus RAS(ON)-Inhibitoren und anderen antineoplastischen Substanzen in Patienten mit RAS-mutierten NSCLC","Status":"active","Phase":"Phase I/II","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"KRAS, NRAS, HRAS","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert, Erstdiagnose, Rezidiv/Refraktär","Therapielinie":"Keine","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Damian Rieke Lang","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06162221","EudraCT-Nr":"2023-509571-16-00","Sponsor":"Revolution Medicines, Inc.","Studienbeginn":"2025-01-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06162221"},{"Studiencode":"06170788","Studiencode_Anzeige":"20023274","Kurzbezeichnung":"MK-2870-007","Studientitel":"A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"PD-L1","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06170788","EudraCT-Nr":"2023-503376-24-00","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2025-03-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06170788"},{"Studiencode":"04628026","Studiencode_Anzeige":"20019003","Kurzbezeichnung":"AMLSG 31-19","Studientitel":"A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":null,"Histologischer Typ":"AML","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Jan Krönke","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT04628026","EudraCT-Nr":"2020-004453-71","Sponsor":"University of Ulm","Studienbeginn":"2024-03-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04628026"},{"Studiencode":"06422143","Studiencode_Anzeige":"20024442","Kurzbezeichnung":"MK-2870-023","Studientitel":"Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06422143","EudraCT-Nr":"2023-510128-66","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2024-10-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06422143"},{"Studiencode":"06758401","Studiencode_Anzeige":"20025897","Kurzbezeichnung":"C5751003","Studientitel":"An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants With Pd-L1 High (=50% Of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer (Be6a Lung-02)","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"PD-L1","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06758401","EudraCT-Nr":"2024-517968-36-00","Sponsor":"Pfizer  (Pfizer)","Studienbeginn":"2026-01-26 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06758401"},{"Studiencode":"05331521","Studiencode_Anzeige":"20015223","Kurzbezeichnung":"IMPROVE CODEL/NOA-18","Studientitel":"IMPROVE CODEL: Verbesserung des funktionellen Ergebnisses für PatientInnen mit neu diagnostizierten Grad II oder III-Gliom mit Kodeletion von 1p/19q: die NOA-18-Studie","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":"1p/19q-Kodeletion, IDH1, IDH2","Histologischer Typ":"Hirntumor","Therapiesetting":"Erstdiagnose","Therapielinie":"1st line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"Dr. med. Martin Misch","Ansprechpartner_Name":null,"Ansprechpartner_Email":"heike.schneider@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05331521","EudraCT-Nr":"2018-005027-16","Sponsor":"University of Heidelberg","Studienbeginn":"2023-02-08 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05331521"},{"Studiencode":"20235039385200","Studiencode_Anzeige":"20022861","Kurzbezeichnung":"PerSurge","Studientitel":"Phase-2-Studie zur Perampanel-Behandlung im Zusammenhang mit chirurgischen Eingriffen bei Patienten mit progressivem Glioblastom","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":"2nd line, 3rd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"PD Dr. med. Julia Onken","Ansprechpartner_Name":null,"Ansprechpartner_Email":"heike.schneider@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-503938-52-00","Sponsor":"University of Heidelberg","Studienbeginn":"2024-10-02 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235039385200"},{"Studiencode":"20245123201100","Studiencode_Anzeige":"20019961","Kurzbezeichnung":"PRIMA-CNS","Studientitel":"Altersangepasste Hochdosis-Chemotherapie gefolgt von autologer Stammzelltransplantation oder konventionelle Chemotherapie mit R-MP als Erstlinienbehandlung bei älteren Patienten mit primärem ZNS-Lymphom - eine randomisierte Phase-III-Studie","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"ZNS-Lymphom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Stefan Habringer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":null,"EudraCT-Nr":"2020-001181-10","Sponsor":"University of Freiburg  (University of Freiburg)","Studienbeginn":"2024-03-12 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245123201100"},{"Studiencode":"07231458","Studiencode_Anzeige":"20024919","Kurzbezeichnung":"ABX-001","Studientitel":"A Phase I/Ib Open-Label Study of ABX-001 Administered With and Without the Anti-PD-1 Immune Checkpoint Inhibitor Pembrolizumab in Participants With Advanced Solid Tumors Who Are Beyond Standard of Care","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"Andere","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT07231458","EudraCT-Nr":"2024-512403-39-01","Sponsor":"Abalos Therapeutics GmbH","Studienbeginn":"2025-12-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07231458"},{"Studiencode":"20235092921700","Studiencode_Anzeige":"20023131","Kurzbezeichnung":"Lobster","Studientitel":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer","Status":"active","Phase":"Phase II","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"HER2, HR, Ki67","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"brustzentrum-studienzentrum@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664485","ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-509292-17-00","Sponsor":"German Breast Group","Studienbeginn":"2025-08-21 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235092921700"},{"Studiencode":"06561386","Studiencode_Anzeige":"20024049","Kurzbezeichnung":"CA224-1093","Studientitel":"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression = 1%","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"PD-L1","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06561386","EudraCT-Nr":"2024-513682-40","Sponsor":"Bristol-Myers Squibb","Studienbeginn":"2026-01-09 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06561386"},{"Studiencode":"05332561","Studiencode_Anzeige":"20021998","Kurzbezeichnung":"COGNITION-GUIDE","Studientitel":"COGNITION-GUIDE - Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer. A multicenter, open-label, umbrella phase-II study","Status":"active","Phase":"Phase II","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"MSI, PD-L1, BRCA1, BRCA2, HER2, HR, PALB2, PI3K-AKT, PIK3CA, TROP2","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"brustzentrum-studienzentrum@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664485","ClinTrials.gov identifier":"NCT05332561","EudraCT-Nr":"2020-002606-22","Sponsor":"DKFZ","Studienbeginn":"2025-04-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/05332561"},{"Studiencode":"06136624","Studiencode_Anzeige":"20022668","Kurzbezeichnung":"Omaha-003 MK5684-003","Studientitel":"A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy","Status":"active","Phase":"Phase III","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":"Sonstiges","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"3rd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marlies.milke@charite.de","Ansprechpartner_Telefon":"'+49 30 450 615 297","ClinTrials.gov identifier":"NCT06136624","EudraCT-Nr":"2023-504899-25","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2024-06-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06136624"},{"Studiencode":"05443126","Studiencode_Anzeige":"20026558","Kurzbezeichnung":"EP0031-101","Studientitel":"A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies","Status":"active","Phase":"Phase I/II","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"RET","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"2nd line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Damian Rieke Lang","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT05443126","EudraCT-Nr":"2022-001258-43","Sponsor":"Ellipses Pharma","Studienbeginn":"2026-02-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05443126"},{"Studiencode":"06140875","Studiencode_Anzeige":"3000829","Kurzbezeichnung":"Brain-RF","Studientitel":"Amplitude modulated radiofrequency electromagnetic field treatment combined with radiochemotherapy and maintenance chemotherapy in patients with glioblastoma (Brain-RF)","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. med. Pirus Ghadjar","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06140875","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-03-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06140875"},{"Studiencode":"06252753","Studiencode_Anzeige":"20022647","Kurzbezeichnung":"LIVER-R","Studientitel":"An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06252753","EudraCT-Nr":null,"Sponsor":"AstraZeneca","Studienbeginn":"2024-11-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06252753"},{"Studiencode":"05183035","Studiencode_Anzeige":"20019435","Kurzbezeichnung":"ITCC-101_APAL2020D","Studientitel":"A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"FLT3","Histologischer Typ":"AML","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. Andrej Lissat","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05183035","EudraCT-Nr":"2021-003212-11","Sponsor":"Princess Máxima Center for Pediatric Oncology","Studienbeginn":"2025-09-04 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05183035"},{"Studiencode":"06821958","Studiencode_Anzeige":"3001693","Kurzbezeichnung":"Immune-RF","Studientitel":"Einarmige Phase II Studie zur Kombination aus kapazitiver Radiofrequenzhyperthermie und Immuntherapie mit Tremelimumab und Durvalumab (STRIDE) bei Patient:innen mit inoperablem hepatozellulären Karzinom","Status":"active","Phase":"Phase II","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. med. Pirus Ghadjar","Ansprechpartner_Name":null,"Ansprechpartner_Email":"yvonne.saewe@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06821958","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2025-04-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06821958"},{"Studiencode":"05192655","Studiencode_Anzeige":"3000468","Kurzbezeichnung":"KIVAL-KHT","Studientitel":"Künstliche Intelligenz (KI) in Der Funktionellen Bildgebung Zur Individualisierten Behandlung Von Kopf-Hals-Plattenepithelkarzinom-Patienten","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Dr. med. Patrick Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05192655","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-11-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05192655"},{"Studiencode":"06922383","Studiencode_Anzeige":"20024573","Kurzbezeichnung":"ISO-CC-010","Studientitel":"A Phase 1b/2 Study of Arfolitixorin Combined With 5-fluorouracil, Oxaliplatin, and Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer","Status":"active","Phase":"Phase I/II","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"KRAS, NRAS, HRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Sebastian Stintzing","Ansprechpartner_Name":null,"Ansprechpartner_Email":"portalambulanz@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 132","ClinTrials.gov identifier":"NCT06922383","EudraCT-Nr":"2024-516802-43-00","Sponsor":"Isofol Medical AB","Studienbeginn":"2025-04-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06922383"},{"Studiencode":"20025932","Studiencode_Anzeige":"20025932","Kurzbezeichnung":"CATCH (mBC)","Studientitel":"Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. med. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"DKFZ","Studienbeginn":"2024-03-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20025932"},{"Studiencode":"05652348","Studiencode_Anzeige":"20024438","Kurzbezeichnung":"HiSTEP1","Studientitel":"Prädiktion des Ansprechens auf Hypertherme Intraperitoneale Chemotherapie in gastrointestinalen Krebserkrankungen (Hi-STEP1)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Beate Rau; Prof. Dr. Beate Rau","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05652348","EudraCT-Nr":null,"Sponsor":"University of Dresden","Studienbeginn":"2025-09-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/05652348"},{"Studiencode":"05327543","Studiencode_Anzeige":"20010860","Kurzbezeichnung":"YoMa","Studientitel":"Effekte zwei verschiedener Yoga-Interventionen auf die Lebensqualität bei Patientinnen mit Brustkrebs im Vergleich zur Warteliste – eine dreiarmige, randomisiert-kontrollierte Studie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie","PI":"Univ.-Prof. Dr. Andreas Michalsen","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05327543","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-05-09 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05327543"},{"Studiencode":"20014792","Studiencode_Anzeige":"20014792","Kurzbezeichnung":"Cardia","Studientitel":"Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II: Transthoracic esophagectomy vs. transhiatal extended gastrectomy.","Status":"active","Phase":"Phase IV","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Allgemein- und Viszeralchirurgie","PI":"Prof. Dr. Johann Pratschke; Prof. Dr. Johann Pratschke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Cologne","Studienbeginn":"2021-08-23 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20014792"},{"Studiencode":"20024285","Studiencode_Anzeige":"20024285","Kurzbezeichnung":"DECIDE-II","Studientitel":"Entscheidung für oder gegen eine Anti-PD-1-Behandlung im adjuvanten Setting von Patienten mit reseziertem Melanom im Stadium IIB/IIC in ganz Europa","Status":"active","Phase":"Phase IIa","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Max Simon Schlaak; Prof. Dr. Max Simon Schlaak","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2025-01-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024285"},{"Studiencode":"3000294","Studiencode_Anzeige":"3000294","Kurzbezeichnung":"DGMKG – BCC","Studientitel":"Klinische Beobachtungsstudie zur Untersuchung der Effizienz verschiedener üblicher Defektdeckungsvarianten nach Resektion von Basalzellkarzinomen im Gesichtsbereich","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Basalzellkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie","PI":"Prof. Dr. Dr. Max Heiland; Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Frankfurt  (University of Frankfurt)","Studienbeginn":"2021-06-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000294"},{"Studiencode":"01252485","Studiencode_Anzeige":"3001052","Kurzbezeichnung":"AMLSG-BiO","Studientitel":"Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leukämie und verwandten Vorläufer- Neoplasien und der akuten Leukämie unklarer Linienzugehörigkeit: Das AMLSG Biology and Outcome (BiO)-Projekt","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"AML","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Jörg Westermann; Prof. Dr. med. Jörg Westermann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT01252485","EudraCT-Nr":null,"Sponsor":"University of Ulm","Studienbeginn":"2011-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/01252485"},{"Studiencode":"06116019","Studiencode_Anzeige":"3000902","Kurzbezeichnung":"ART-02","Studientitel":"Machbarkeit der Strahlentherapie an einem neuartigen CTadaptiven Linearbeschleuniger (ETHOS)","Status":"active","Phase":"Phase II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Daniel Zips","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06116019","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-08-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06116019"},{"Studiencode":"05503797","Studiencode_Anzeige":"20020695","Kurzbezeichnung":"FORE8394","Studientitel":"A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations","Status":"active","Phase":"Phase II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"BRAF","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT05503797","EudraCT-Nr":"2022-000627-20","Sponsor":"Fore Biotherapeutics","Studienbeginn":"2024-01-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05503797"},{"Studiencode":"05253651","Studiencode_Anzeige":"20019334","Kurzbezeichnung":"SGNTUC-029 (MOUNTAINEER-03)","Studientitel":"An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"HER2","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT05253651","EudraCT-Nr":"2021-002672-40","Sponsor":"Seagen Inc.","Studienbeginn":"2025-03-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05253651"},{"Studiencode":"20017345","Studiencode_Anzeige":"20017345","Kurzbezeichnung":"DNPM - quantitative Evaluation","Studientitel":"Deutsches Netzwerk für Personalisierte Medizin","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Prof. Dr. Ulrich Keilholz; PD Dr. med. Damian Tobias Rieke Lang","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gemeinsamer Bundesausschuss","Studienbeginn":"2023-01-09 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017345"},{"Studiencode":"06282575","Studiencode_Anzeige":"20023322","Kurzbezeichnung":"JZP598-302","Studientitel":"An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Canc","Status":"active","Phase":"Phase III","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"HER2","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06282575","EudraCT-Nr":"2023-508219-21-00","Sponsor":"Jazz Pharmaceuticals, Inc.","Studienbeginn":"2025-11-19 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06282575"},{"Studiencode":"04111978","Studiencode_Anzeige":"20019909","Kurzbezeichnung":"ENGOT-ov54 / Swiss-GO-2 / AGO OVAR 26 / AGO 65 (MATAO)","Studientitel":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial, Including LOGOS (Low Grade Ovarian Cancer Sub-study).","Status":"active","Phase":"Phase III","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT04111978","EudraCT-Nr":"2019-002264-27","Sponsor":"Swiss GO Trial Group","Studienbeginn":"2024-06-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04111978"},{"Studiencode":"3000404","Studiencode_Anzeige":"3000404","Kurzbezeichnung":"Tumordatenbank","Studientitel":"Datenbank für die Erfassung und Auswertung der Daten von Patient*innen mit Tumorerkrankung im Kopf-Hals-Bereich","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie","PI":"Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000404"},{"Studiencode":"3001217","Studiencode_Anzeige":"3001217","Kurzbezeichnung":"Biomaterialsammlung von Patienten mit Kopf-Hals-Tumor","Studientitel":"Biomaterialsammlung von Patienten mit Kopf-Hals-Tumor zur wissenschaftlichen Untersuchung","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"TP53;Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie","PI":"Prof. Dr. Dr. Max Heiland; Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2020-06-29 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001217"},{"Studiencode":"04098146","Studiencode_Anzeige":"20020299","Kurzbezeichnung":"SMDR","Studientitel":"International, Multicenter, Prospective Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction (SMDR) Following Oral Squamous Cell Carcinoma (OSSC) Resection","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie","PI":"Prof. Dr. Dr. Max Heiland; Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT04098146","EudraCT-Nr":null,"Sponsor":"AO Innovation Translation Center","Studienbeginn":"2023-06-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04098146"},{"Studiencode":"06189898","Studiencode_Anzeige":"3000889","Kurzbezeichnung":"FIRASE","Studientitel":"Funktionelle Bildgebung zur Identifizierung von strahlenempfindlichem Speiseroehrenkrebs - eine Biomarker-Validierungsstudie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom, Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"PD Dr. med. Sebastian Zschaeck; PD Dr. med. Sebastian Zschaeck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06189898","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-03-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06189898"},{"Studiencode":"06353386","Studiencode_Anzeige":"20023271","Kurzbezeichnung":"Umbrella U01","Studientitel":"MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)","Status":"active","Phase":"Phase I/II","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"2nd line, 3rd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marlies.milke@charite.de","Ansprechpartner_Telefon":"'+49 30 450 615 297","ClinTrials.gov identifier":"NCT06353386","EudraCT-Nr":"2023-506288-33","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2025-04-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06353386"},{"Studiencode":"06091254","Studiencode_Anzeige":"20023239","Kurzbezeichnung":"R1979-HM-2298 (OLYMPIA-1)","Studientitel":"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Corinna Leng","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT06091254","EudraCT-Nr":"2022-502660-20-00","Sponsor":"Regeneron Pharmaceuticals","Studienbeginn":"2025-03-11 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06091254"},{"Studiencode":"06925737","Studiencode_Anzeige":"20025770","Kurzbezeichnung":"MK2400-001","Studientitel":"A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Status":"active","Phase":"Phase III","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marlies.milke@charite.de","Ansprechpartner_Telefon":"'+49 30 450 615 297","ClinTrials.gov identifier":"NCT06925737","EudraCT-Nr":"2024-517423-40-00","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2025-09-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06925737"},{"Studiencode":"05203172","Studiencode_Anzeige":"20020988","Kurzbezeichnung":"C4221026 (FLOTILLA)","Studientitel":"Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study)","Status":"active","Phase":"Phase IV","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT05203172","EudraCT-Nr":"2021-004395-34","Sponsor":"Pfizer  (Pfizer)","Studienbeginn":"2023-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05203172"},{"Studiencode":"04925609","Studiencode_Anzeige":"20018981","Kurzbezeichnung":"BrigaPed","Studientitel":"A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors","Status":"active","Phase":"Phase I/II","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"1st line, 2nd line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Anne Thorwarth","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT04925609","EudraCT-Nr":"2021-002713-34","Sponsor":"Universitätsklinikum Hamburg-Eppendorf  (Universitätsklinikum Hamburg-Eppendorf)","Studienbeginn":"2023-12-28 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04925609"},{"Studiencode":"3000107","Studiencode_Anzeige":"3000107","Kurzbezeichnung":"LB_HTCC_MCC","Studientitel":"Liquid Biopsy zur Überwachung von Patienten mit einem Merkelzell-Karzinom","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Merkel Cell Carcinoma","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Kamran Ghoreschi; Dr. rer. nat. Franz Joachim Hilke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-10-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000107"},{"Studiencode":"04929223","Studiencode_Anzeige":"20020882","Kurzbezeichnung":"WO42758 (INTRINSIC)","Studientitel":"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","Status":"active","Phase":"Phase I","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT04929223","EudraCT-Nr":"2021-001207-33","Sponsor":"Hoffmann-La Roche  (Hoffmann-La Roche)","Studienbeginn":"2025-06-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04929223"},{"Studiencode":"05827016","Studiencode_Anzeige":"20023064","Kurzbezeichnung":"IM048-022 (EXCALIBER-Maintenance)","Studientitel":"A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Stephan Rainer Maximillian Bohl","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT05827016","EudraCT-Nr":"2022-501515-14-00","Sponsor":"Bristol-Myers Squibb","Studienbeginn":"2025-09-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05827016"},{"Studiencode":"04221542","Studiencode_Anzeige":null,"Kurzbezeichnung":"AMG 509","Studientitel":"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer","Status":"active","Phase":"Phase I","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marlies.milke@charite.de","Ansprechpartner_Telefon":"'+49 30 450 615 297","ClinTrials.gov identifier":"NCT04221542","EudraCT-Nr":"2023-504361-23","Sponsor":"Amgen GmbH  (Amgen GmbH)","Studienbeginn":"2025-08-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04221542"},{"Studiencode":"20225018089600","Studiencode_Anzeige":"20021312","Kurzbezeichnung":"MCL Elderly III","Studientitel":"Venetoclax in Kombination mit dem BTK Inhibitor Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab zur Behandlung eines unbehandelten Mantelzell-Lymphoms bei Patienten, die nicht für eine Hochdosistherapie geeignet sind.","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Mantelzell-Lymphom (MCL)","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Frederik Damm","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":null,"EudraCT-Nr":"2020-002935-30","Sponsor":"University of Mainz  (University of Mainz)","Studienbeginn":"2024-05-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225018089600"},{"Studiencode":"07197307","Studiencode_Anzeige":null,"Kurzbezeichnung":"WWU23_0006 (CLEAR)","Studientitel":"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Diffus großzelliges B-Zell-Lymphom (DLBCL)","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Björn Chapuy","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT07197307","EudraCT-Nr":"2023-509861-19-01","Sponsor":"University of Münster","Studienbeginn":"2025-11-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07197307"},{"Studiencode":"02265770","Studiencode_Anzeige":null,"Kurzbezeichnung":"SIOP Ependymom II","Studientitel":"Eine europäische klinische Studie zur Diagnostik und Behandlung von Kindern, Jugendlichen und jungen Erwachsenen mit einem Ependymom","Status":"active","Phase":"Phase II/III","Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Katja von Hoff","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT02265770","EudraCT-Nr":"2013-002766-39","Sponsor":"andere Uniklinik","Studienbeginn":"2020-02-10 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/02265770"},{"Studiencode":"20235078994700","Studiencode_Anzeige":"20022971","Kurzbezeichnung":"GMALL-Isatuximab","Studientitel":"A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"CD38","Histologischer Typ":"ALL","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Stefan Schwartz","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-507899-47-00","Sponsor":"University of Frankfurt  (University of Frankfurt)","Studienbeginn":"2024-12-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235078994700"},{"Studiencode":"20235102943400","Studiencode_Anzeige":"20025188","Kurzbezeichnung":"CLL18 (MOIRAI)","Studientitel":"Eine multizentrische, randomisierte, prospektive, offene Phase-III-Studie zum Vergleich von zeitlich begrenzter Therapie (12 Zyklen) mit Venetoclax/ Obinutuzumab, zeitlich begrenzter Therapie (15 Zyklen) mit Venetoclax/ Pirtobrutinib und MRD-gesteuerter Therapie mit Venetoclax/ Pirtobrutinib bei Patienten/Patientinnen mit bislang unbehandelter chronischer lymphatischer Leukämie (CLL) oder kleinzelligem lymphozytischem Lymphom (SLL) mit dem Ziel, zu etablieren, dass die Messung der individuellen Resterkrankung zur Steuerung der Behandlungsdauer genutzt wird und dadurch die Behandlungsergebnisse verbessert werden","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"CLL","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Frederik Damm","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-510294-34-00","Sponsor":"University of Cologne","Studienbeginn":"2025-10-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235102943400"},{"Studiencode":"20245105782500","Studiencode_Anzeige":"20021084","Kurzbezeichnung":"SIOP HR-MB","Studientitel":"Internationale, prospektive Studie zu Hochrisiko-Medulloblastomen bei Patienten im Alter von über 3 Jahren","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":"SHH, WNT","Histologischer Typ":"Neuroblastom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. Pablo Hernaiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2018-004250-17","Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2025-06-24 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245105782500"},{"Studiencode":"3000395","Studiencode_Anzeige":"3000395","Kurzbezeichnung":"AA-BMF-Register","Studientitel":"Zentrale Registrierung von Patientendaten und Biomaterialbank bei Aplastischen Anämien und Bone Marrow Failure Syndromen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Aplastische Anämie","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"leo.hansmann@charite.de;   leo.hansmann@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"RWTH Aachen University  (RWTH Aachen University)","Studienbeginn":"2024-01-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000395"},{"Studiencode":"20020803","Studiencode_Anzeige":"20020803","Kurzbezeichnung":"ESORES","Studientitel":"Chirurgie \"as needed\" versus Chirurgie \"on principle\" bei vollständiger Tumorremission nach neoadjuvanter Therapie von Speiseröhrenkrebs","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom, Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"PD Dr. Severin Daum; PD Dr. Severin Daum","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Bielefeld","Studienbeginn":"2024-03-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20020803"},{"Studiencode":"20020239","Studiencode_Anzeige":"20020239","Kurzbezeichnung":"POWER","Studientitel":"Moderate Ganzkörperhyperthermie bei Tumorpatienten: Einfluss auf zirkulierende Tumorzellen, Tumoransprechen, Lebensqualität, Fatigue, Psyche, Immunreaktion und Tumormikromilieu (Potential of moderate whole body Hyperthermia to enhance response)","Status":"active","Phase":"Phase II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"PD Dr. med. Sebastian Zschaeck; PD Dr. med. Sebastian Zschaeck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-01-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20020239"},{"Studiencode":"05949125","Studiencode_Anzeige":"20021128","Kurzbezeichnung":"AVC-201-01","Studientitel":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"CD123","Histologischer Typ":"AML","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Jörg Westermann","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT05949125","EudraCT-Nr":"2022-501797-19-00","Sponsor":"AvenCell Europe GmbH","Studienbeginn":"2024-10-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05949125"},{"Studiencode":"06072781","Studiencode_Anzeige":"20023814","Kurzbezeichnung":"AGO-OVAR 2.46/ENGOT-ov81 (RAMP 301)","Studientitel":"A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer","Status":"active","Phase":"Phase III","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":"KRAS","Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"PD Dr. med. Radoslav Chekerov","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT06072781","EudraCT-Nr":"2023-508204-38","Sponsor":"Verastem, Inc.","Studienbeginn":"2025-02-14 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06072781"},{"Studiencode":"05008809","Studiencode_Anzeige":"20024100","Kurzbezeichnung":"AIO-KRK-0418 (FIRE-9/PORT)","Studientitel":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT05008809","EudraCT-Nr":"2020-006144-18","Sponsor":"Charité","Studienbeginn":"2021-11-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05008809"},{"Studiencode":"3001361","Studiencode_Anzeige":"3001361","Kurzbezeichnung":"SMA-TMS","Studientitel":"Kartierung des supplementär-motorischen Areals mittels repetitiver navigierter transkranieller Magnetstimulation in Patient*innen mit Gehirntumoren","Status":"active","Phase":"Nicht zutreffend","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie CCM","PI":"Melina Julia Engelhardt;  Melina Julia Engelhardt","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-10-27 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001361"},{"Studiencode":"06150157","Studiencode_Anzeige":null,"Kurzbezeichnung":"88549968MPN1001","Studientitel":"A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"CALR","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Philipp le Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06150157","EudraCT-Nr":"2023-505584-36-00","Sponsor":"Janssen Research & Development, LLC","Studienbeginn":"2024-09-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06150157"},{"Studiencode":"20225014562800","Studiencode_Anzeige":"20016755","Kurzbezeichnung":"SIOPE ATRT01","Studientitel":"Internationale, prospektive “Umbrella”-Studie für Kinder und Jugendliche mit atypischen teratoiden/rhabdoiden Tumoren (ATRT) incl. einer randomisierten Phase III-Studie zur Untersuchung der Nichtunterlegenheit von 3 Kursen Hochdosis-Chemotherapie (HDCT) verglichen mit fokaler Strahlentherapie in der Konsolidierung.","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. Pablo Hernaiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2018-003335-29","Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2022-09-05 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225014562800"},{"Studiencode":"3000857","Studiencode_Anzeige":"3000857","Kurzbezeichnung":"OnkoCare Plus","Studientitel":"Prospektive Erhebung von Daten von Patientinnen und Patienten mit verschieden onkologischen Erkrankungen im Rahmen einer Registerstudie, die im Rahmen einer neuen Supportivsprechstunde in unserer Klinik behandelt werden","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-01-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000857"},{"Studiencode":"3000906","Studiencode_Anzeige":"3000906","Kurzbezeichnung":"pROtein","Studientitel":"Einfluss der Proteinaufnahme auf die Muskelmasse und die gesundheitsbezogene Lebensqualität während und nach Erhalt von Strahlentherapie bei Patient:innen mit verschiedenen Tumorerkrankungen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-11-20 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000906"},{"Studiencode":"20225011804000","Studiencode_Anzeige":"20016942","Kurzbezeichnung":"iEuroEwing","Studientitel":"Patients with localised Standard risk SR or metastatic high Risk HR Primary diagnosed Ewing Sarkoma or Ewing-like Sarkoma &lt;50 years of age","Status":"active","Phase":"Phase III","Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"Knochen und Gelenkknorpel","Molekulare Marker":null,"Histologischer Typ":"Ewing-Sarkom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Monika Scheer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2019-004153-93","Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2024-09-06 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225011804000"},{"Studiencode":"3001591","Studiencode_Anzeige":"3001591","Kurzbezeichnung":"Datenbank STS","Studientitel":"Registerstudie zur Datensammlung (Weichteilsarkome)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Mesotheliales Gewebe und Weichteilgewebe","Organsystem_Alias":"weichteilgewebe","Molekulare Marker":null,"Histologischer Typ":"Weichteilsarkom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Anne Flörcken; Prof. Dr. Anne Flörcken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-04-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001591"},{"Studiencode":"20021555","Studiencode_Anzeige":"20021555","Kurzbezeichnung":"EMCL Register","Studientitel":"The Registry of the European Mantle Cell Lymphoma study group - MCL: Disease pattern, treatment algorithms and mechanisms of relapse","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Mantelzell-Lymphom (MCL)","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Olaf Penack; Prof. Dr. med. Olaf Penack","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Mainz  (University of Mainz)","Studienbeginn":"2024-07-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20021555"},{"Studiencode":"20023970","Studiencode_Anzeige":"20023970","Kurzbezeichnung":"TEAM","Studientitel":"Taktilographie Evidenz Analyse Mamma: Prospektive Studie zur Taktilographie als Baustein zur Verbesserung der Frauengesundheit (TEAM)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Brustzentrum","PI":"Dr. Hannah Woopen; Dr. Hannah Woopen","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Bundesministerium für Gesundheit","Studienbeginn":"2025-04-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20023970"},{"Studiencode":"20225014541100","Studiencode_Anzeige":"20015716","Kurzbezeichnung":"ALCL-VBL","Studientitel":"Internationale kooperative prospektive Studie für Kinder und Jugendliche mit Standardrisiko ALK-positiven ALCL zur Wirksamkeit einer Vinblastin Therapie","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":"ALK","Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Torsten Ebeling","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2017-002935-40","Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2025-06-13 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225014541100"},{"Studiencode":"20235080761100","Studiencode_Anzeige":null,"Kurzbezeichnung":"AIO-KRK-0620 (FIRE-10/ PROTECTOR)","Studientitel":"Pre-Operative Treatment in rEseCTable cOlon cancer (PROTECTOR) - Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy preoperative system therapy in advanced colon cancer","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-508076-11-00","Sponsor":"Charité","Studienbeginn":"2025-06-27 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235080761100"},{"Studiencode":"05460000","Studiencode_Anzeige":"20020830","Kurzbezeichnung":"NOGGO-ov53 (N-Plus)","Studientitel":"A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy","Status":"active","Phase":"Phase II","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":"HRD","Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT05460000","EudraCT-Nr":"2022-502559-69-00","Sponsor":"Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V. (NOGGO)","Studienbeginn":"2025-02-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05460000"},{"Studiencode":"01356290","Studiencode_Anzeige":null,"Kurzbezeichnung":"MEMMAT","Studientitel":"A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT01356290","EudraCT-Nr":"2010-023691-33","Sponsor":"andere Uniklinik","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/01356290"},{"Studiencode":"04837859","Studiencode_Anzeige":"20022502","Kurzbezeichnung":"INDIE","Studientitel":"Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Hodgkin Lymphom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Stephan Mathas","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT04837859","EudraCT-Nr":"2021-000330-33","Sponsor":"University of Cologne","Studienbeginn":"2024-08-19 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04837859"},{"Studiencode":"06586515","Studiencode_Anzeige":"20024323","Kurzbezeichnung":"J5J-OX-JZZA","Studientitel":"A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"KRAS","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06586515","EudraCT-Nr":"2024-516440-25-00","Sponsor":"Eli Lilly and Company","Studienbeginn":"2025-10-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06586515"},{"Studiencode":"06303505","Studiencode_Anzeige":"20024007","Kurzbezeichnung":"NAPISTAR1-01","Studientitel":"First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety,Tolerability,PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer or r/r Adenocarcinoma Non-small Cell Lung Cancer","Status":"active","Phase":"Phase I/II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"NSCLC, Ovarialkarzinom","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT06303505","EudraCT-Nr":"2024-511074-80","Sponsor":"Tubulis GmbH","Studienbeginn":"2024-10-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06303505"},{"Studiencode":"04104607","Studiencode_Anzeige":null,"Kurzbezeichnung":"PSMAxCD3 (DKTK-PMO-1605)","Studientitel":"First in Human Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Cancer","Status":"active","Phase":"Phase I","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Nonmetastatic Castration-Resistant Prostate Cancer","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT04104607","EudraCT-Nr":null,"Sponsor":"Universitätsklinikum Tübingen  (Universitätsklinikum Tübingen)","Studienbeginn":"2022-06-22 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04104607"},{"Studiencode":"05583071","Studiencode_Anzeige":"20023204","Kurzbezeichnung":"MTR²","Studientitel":"Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Stefan Habringer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT05583071","EudraCT-Nr":null,"Sponsor":"University of Cologne","Studienbeginn":"2025-06-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05583071"},{"Studiencode":"03396718","Studiencode_Anzeige":"20019932","Kurzbezeichnung":"DELPHI (STR-DELPHI-2016)","Studientitel":"De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity","Status":"active","Phase":"Phase I","Organsystem":"Kopf-Hals","Organsystem_Alias":"Kopf-Hals","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Dr. med. Marcus Beck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT03396718","EudraCT-Nr":null,"Sponsor":"University of Dresden","Studienbeginn":"2025-10-29 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/03396718"},{"Studiencode":"20260508C191","Studiencode_Anzeige":null,"Kurzbezeichnung":"COSS-Register","Studientitel":"COSS-Register: Clinical Registry for children, adolescents and adults with Osteosarcoma and Bone Tumors","Status":"active","Phase":null,"Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"knochen","Molekulare Marker":null,"Histologischer Typ":"Osteosarkom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Monika Scheer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Cooperative Osteosarcoma Study Group (COSS)  (Cooperative Osteosarcoma Study Group (COSS))","Studienbeginn":"2012-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260508C191"},{"Studiencode":"05867927","Studiencode_Anzeige":"20022091","Kurzbezeichnung":"GENERATE","Studientitel":"Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications - A prospective, non interventional, mulit-center, post market clinical study","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"weibliches genitale","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. Mustafa Zelal Muallem","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT05867927","EudraCT-Nr":null,"Sponsor":"Intuitive Surgical, Sàrl","Studienbeginn":"2024-01-11 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05867927"},{"Studiencode":"00662090","Studiencode_Anzeige":null,"Kurzbezeichnung":"EWOG-MDS 2006","Studientitel":"Prospective non-randomized multi-center study for epidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"MDS","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Annette Künkele","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT00662090","EudraCT-Nr":null,"Sponsor":"University of Freiburg  (University of Freiburg)","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/00662090"},{"Studiencode":"02417324","Studiencode_Anzeige":null,"Kurzbezeichnung":"I-HIT-MED Registry","Studientitel":"International HIT-MED Registry: For children, adolescents, and adults with medulloblastoma, ependymoma, pineoblastoma, CNS-primitive neuroectodermal tumours","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT02417324","EudraCT-Nr":null,"Sponsor":"Universitätsklinikum Hamburg-Eppendorf  (Universitätsklinikum Hamburg-Eppendorf)","Studienbeginn":"2015-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/02417324"},{"Studiencode":"05993910","Studiencode_Anzeige":null,"Kurzbezeichnung":"Hyperthermie Registerstudie","Studientitel":"Prospektive Hyperthermie-Datenbank bei Krebspatienten (HTRegister)","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. med. Pirus Ghadjar","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05993910","EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2014-10-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05993910"},{"Studiencode":"05852522","Studiencode_Anzeige":null,"Kurzbezeichnung":"NCT/DKTK-MASTER","Studientitel":"NCT/DKTK-MASTER;Molecular aided stratification for tumor eradication research","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"helga.hammerschmidt@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 682","ClinTrials.gov identifier":"NCT05852522","EudraCT-Nr":null,"Sponsor":"DKTK","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/05852522"},{"Studiencode":"02686229","Studiencode_Anzeige":null,"Kurzbezeichnung":"LoG-Glio","Studientitel":"Multizentrische Registerstudie zum epidemiologischen und biologischen Erkrankungsprofil sowie zum klinischen Verlauf bei niedriggradigen Gliomen","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"PD Dr. med. Julia Onken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT02686229","EudraCT-Nr":null,"Sponsor":"University of Ulm","Studienbeginn":"2018-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/02686229"},{"Studiencode":"20260508C206","Studiencode_Anzeige":null,"Kurzbezeichnung":"PRECON","Studientitel":"Prekonditionierung motorischer Areale mittels repetitiver navigierter transkranieller Magnetstimulation (rnTMS) zur Verbesserung des neuro-onkologischen und funktionellen Outcomes","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"Prof. Dr. Thomas Picht","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-03-13 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260508C206"},{"Studiencode":"3001604","Studiencode_Anzeige":"3001604","Kurzbezeichnung":"GerPaCyst","Studientitel":"A German Club Cyst Registry - Aufdeckung der natürlichen entitätsspezifischen Biologie von Pankreaszysten und daraus resultierende Errechnung eines Risikomodells zur Beurteilung des individuellen Malignitätspotentials","Status":"active","Phase":null,"Organsystem":"Pankreas","Organsystem_Alias":"Pankreas","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Allgemein- und Viszeralchirurgie","PI":"PD Dr. med. Matthäus Felsenstein","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Schleswig-Holstein  (University of Schleswig-Holstein)","Studienbeginn":"2025-01-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001604"},{"Studiencode":"02872987","Studiencode_Anzeige":null,"Kurzbezeichnung":"GMALL Register","Studientitel":"GMALL-REGISTER Nicht-interventionelle Studie mit begleitender Biomaterialbank","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Stefan Schwartz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT02872987","EudraCT-Nr":null,"Sponsor":"University of Frankfurt  (University of Frankfurt)","Studienbeginn":"2010-01-02 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/02872987"},{"Studiencode":"20260508C209","Studiencode_Anzeige":null,"Kurzbezeichnung":"Pediatric Targeted Therapy 2.0 (PTT 2.0)","Studientitel":"Pediatric Targeted Therapy 2.0 - Verbesserung der Diagnose und Targetanalyse bei progressiven oder rückfälligen pädiatrischen Tumoren","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Heidelberg","Studienbeginn":"2021-07-14 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260508C209"},{"Studiencode":"20026503","Studiencode_Anzeige":"20026503","Kurzbezeichnung":"CNS-InterREST GPOH","Studientitel":"Internationales Register für seltene Embryonale und Sarkomatöse Tumoren des ZNS","Status":"active","Phase":"Nicht zutreffend","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. Barbara Zezschwitz; Dr. Barbara Zezschwitz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2025-08-14 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20026503"},{"Studiencode":"20260508C211","Studiencode_Anzeige":null,"Kurzbezeichnung":"LOGGIC-Core","Studientitel":"Register für molekulare und klinische Daten für pädiatrische niedriggradige Gliome (LGG)","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"gehirn","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Heidelberg","Studienbeginn":"2021-01-22 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260508C211"},{"Studiencode":"20260508C212","Studiencode_Anzeige":null,"Kurzbezeichnung":"NOGGO ov45 (CAROLIN)","Studientitel":"Nicht-interventionelle Beobachtungsstudie zur Erfassung von Krankheits-, Patientinnen und Behandlungscharakteristika bei Langzeitüberlebenden mit Eierstockkrebs","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Erstdiagnose, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V. (NOGGO)","Studienbeginn":"2022-11-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260508C212"},{"Studiencode":"06855134","Studiencode_Anzeige":"20025685","Kurzbezeichnung":"RATIONALE","Studientitel":"Randomized Comparison of Treatment Guided by Comprehensive Genome and Transcriptome Analysis versus Standard of Care in Patients with Advanced Rare Cancers (RATIONALE)","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"helga.hammerschmidt@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 682","ClinTrials.gov identifier":"NCT06855134","EudraCT-Nr":null,"Sponsor":"National Center for Tumor Diseases, Heidelberg","Studienbeginn":"2025-10-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/06855134"},{"Studiencode":"20013893","Studiencode_Anzeige":"20013893","Kurzbezeichnung":"HIT-LOGGIC Register","Studientitel":"HIT-LOGGIC Register: Prospektives multizentrisches Register für Kinder und Jugendliche mit einem niedrig-gradigen Gliom","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"gehirn","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2019-02-15 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20013893"},{"Studiencode":"3001536","Studiencode_Anzeige":"3001536","Kurzbezeichnung":"ALL-BFM Register","Studientitel":"Registerprotokoll des ALL-BFM-Registers zur Erfassung von Daten von Kindern und Jugendlichen mit akuter lymphoblastischer Leukämie in Deutschland","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2024-10-23 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001536"},{"Studiencode":"3001780","Studiencode_Anzeige":"3001780","Kurzbezeichnung":"PREPRO (Prähab Prostata)","Studientitel":"Qualitative Erhebung zur Erfassung der Bedürfnisse von Patienten und deren Angehörigen während und nach einer Strahlentherapie bei Prostatakarzinomerkrankung und deren Einstellung und Wünsche bezüglich einer Prähabilitationsmaßnahme","Status":"active","Phase":null,"Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2025-10-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001780"},{"Studiencode":"20017719","Studiencode_Anzeige":"20017719","Kurzbezeichnung":"BMBC (GBG 79)","Studientitel":"Brain Metastases in Breast Cancer Network Germany","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. med. Maria Margarete Karsten","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"German Breast Group","Studienbeginn":"2023-02-02 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017719"},{"Studiencode":"3001063","Studiencode_Anzeige":"3001063","Kurzbezeichnung":"Strategien zur Expansion und Funktionssteigerung (T-Cell)","Studientitel":"Identifizierung optimierter Strategien zur Expansion und Funktionssteigerung von T-Zellen für die adoptive T-Zelltherapie","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2019-03-21 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001063"},{"Studiencode":"20015776","Studiencode_Anzeige":"20015776","Kurzbezeichnung":"Survivorship Clinic","Studientitel":"Sprechstunde für Langzeitüberlebende mit gynäkologischer Tumorerkrankung","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Dr. med. Hannah Woopen, MSc","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-05-31 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20015776"},{"Studiencode":"3000671","Studiencode_Anzeige":"3000671","Kurzbezeichnung":"ART 01","Studientitel":"Entwicklung einer digitalen Anwendung für die automatisierte adaptive Präzisionsstrahlentherapie des Lungenkarzinoms mit Patientenfeedback","Status":"active","Phase":null,"Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Daniel Zips","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-11-29 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000671"},{"Studiencode":"3001527","Studiencode_Anzeige":"3001527","Kurzbezeichnung":"SD-CA Register (AIO-YMO/ENC-0216-ThyCa)","Studientitel":"Register und Biobank für seltene maligne Tumore der Schilddrüse und Nebenschilddrüsen","Status":"active","Phase":null,"Organsystem":"Endokrine Drüsen","Organsystem_Alias":"Endokrine Drüsen","Molekulare Marker":null,"Histologischer Typ":"Schilddrüsenkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik für Endokrinologie und Stoffwechselmedizin","PI":"Dr. med. Dominik Soll","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"LMU München  (LMU München)","Studienbeginn":"2025-05-22 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001527"},{"Studiencode":"3001507","Studiencode_Anzeige":"3001507","Kurzbezeichnung":"iHIT-HGG Register","Studientitel":"Internationales Register der HIT-HGG Studiengruppe für pädiatrische Patienten und junge Erwachsene mit hochgradigem Gliom","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2025-11-13 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001507"},{"Studiencode":"3001059","Studiencode_Anzeige":"3001059","Kurzbezeichnung":"LyData","Studientitel":"Untersuchungen zur Entwicklung personalisierter Lymphomtherapien","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2018-10-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001059"},{"Studiencode":"3001058","Studiencode_Anzeige":"3001058","Kurzbezeichnung":"Immune checkpoint Blockade (ICB)","Studientitel":"Pilotstudie zur Untersuchung des Einflusses von Tumorentität und Immun-Checkpoint Therapie auf Immunfunktion","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2019-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001058"},{"Studiencode":"20245158846900","Studiencode_Anzeige":"20025319","Kurzbezeichnung":"GS-US-600-6165","Studientitel":"A Global, Multicenter, Randomized, Open-label, Phase 3 study of Sacituzumab Govitecan versus Standard of Care (SoC) in Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin","PI":"PD Dr. med. Nikolaj Frost; PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-515884-69","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245158846900"},{"Studiencode":"20245187611000","Studiencode_Anzeige":"20025706","Kurzbezeichnung":"MK3475-U01H","Studientitel":"KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants with Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)","Status":"active","Phase":"Phase II","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin","PI":"PD Dr. med. Nikolaj Frost; PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-518761-10","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245187611000"},{"Studiencode":"20245188391100","Studiencode_Anzeige":"20025707","Kurzbezeichnung":"MK3475-U01I","Studientitel":"KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)","Status":"active","Phase":"Phase II","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin","PI":"PD Dr. med. Nikolaj Frost; PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-518839-11","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245188391100"},{"Studiencode":"20235090764200","Studiencode_Anzeige":"20025713","Kurzbezeichnung":"GEM-Neo 2302","Studientitel":"Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma","Status":"active","Phase":"Phase II","Organsystem":"Auge","Organsystem_Alias":"auge","Molekulare Marker":"HLA","Histologischer Typ":"Aderhautmelanom","Therapiesetting":"Neoadjuvant","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Dr. med. Caroline Anna Peuker; Dr. med. Caroline Anna Peuker","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-509076-42-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235090764200"},{"Studiencode":"20225031404100","Studiencode_Anzeige":"20022081","Kurzbezeichnung":"IOV MEL-301","Studientitel":"IOV MEL-301","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"Sonstiges","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2022-503140-41-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225031404100"},{"Studiencode":"20255219276300","Studiencode_Anzeige":"20019939","Kurzbezeichnung":"MyD88L265P-TCR","Studientitel":"Precision immunotherapy for MyD88L265P-mutated lymphoma","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Metastasiert","Therapielinie":"2nd line, 3rd line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-521927-63-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255219276300"},{"Studiencode":"20245173001001","Studiencode_Anzeige":"3000235","Kurzbezeichnung":"Flot 9/HIPEC","Studientitel":"Vorhersage der Hämatotoxizität und nicht-hämatologischen Toxizität von perioperativen Systemtherapien sowie weiteren klinischen Outcome-Parametern bei Patienten mit lokal fortgeschrittenem Karzinom des Magens oder gastroösophagealen Übergang (AEG I-III nach Siewert)","Status":"active","Phase":"Phase III","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"gastroösophagealer übergang","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie (einschl. Arbeitsbereich Ernährungsmedizin) CBF","PI":"PD Dr. Severin Daum; PD Dr. Severin Daum","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2017-003832-35","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245173001001"},{"Studiencode":"20245148652000","Studiencode_Anzeige":"3000914","Kurzbezeichnung":"PRIDE","Studientitel":"PRIDE – PRotective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma","Status":"active","Phase":"Phase IIa","Organsystem":"ZNS","Organsystem_Alias":"gehirn","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"PD Dr. David Kaul; PD Dr. David Kaul","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2021-000565-32","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245148652000"},{"Studiencode":"05935384","Studiencode_Anzeige":"20024150","Kurzbezeichnung":"06-MX-001 (SYBIL)","Studientitel":"SYBIL: obServation of therapy with lIquis Biopsy evaLuation","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CCM","PI":"Prof. Dr. med. Sebastian Stintzing; Prof. Dr. med. Sebastian Stintzing","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05935384","EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05935384"},{"Studiencode":"202100540526","Studiencode_Anzeige":"20021210","Kurzbezeichnung":"MK-3475-U06A","Studientitel":"Protocol Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naive to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A","Status":"active","Phase":"Phase I/II","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"speiseröhre","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Dr. med. Annika Kurreck; Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2021-005405-26","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/202100540526"},{"Studiencode":"06175845","Studiencode_Anzeige":"20023815","Kurzbezeichnung":"Acticca-2","Studientitel":"Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"gallengang","Molekulare Marker":null,"Histologischer Typ":"Gallengangskarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. Dominik Paul Modest; Prof. Dr. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06175845","EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06175845"},{"Studiencode":"3000777","Studiencode_Anzeige":"3000777","Kurzbezeichnung":"scRNAM","Studientitel":"Zelluläre Veränderungen beim Naevus-assoziierten Melanom","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Dr. med. Rose Moritz; Dr. med. Rose Moritz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000777"},{"Studiencode":"20023817","Studiencode_Anzeige":"20023817","Kurzbezeichnung":"ParaMF","Studientitel":"“Parapsoriasis or Mycosis fungoides can we end the discussion? Hypothesis: Parapsoriasis is a variant of Mycosis fungoides","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"CD3","Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Dr. med. Rose Moritz; Dr. med. Rose Moritz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20023817"},{"Studiencode":"20021211","Studiencode_Anzeige":"20021211","Kurzbezeichnung":"MK-3475-06B","Studientitel":"Protocol Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B.","Status":"active","Phase":"Phase I/II","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"ösophagus","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Dr. med. Annika Kurreck; Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20021211"},{"Studiencode":"20016754","Studiencode_Anzeige":"20016754","Kurzbezeichnung":"MK-6482","Studientitel":"A Phase 2 Study to Evaluate the Efficacy and Safety of MK-6482 Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET)","Status":"active","Phase":"Phase III","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Neuroendokrin (NET and NEC)","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik für Endokrinologie CCM","PI":"Prof. Dr. Knut Mai; Prof. Dr. Knut Mai","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20016754"},{"Studiencode":"20260615C487","Studiencode_Anzeige":null,"Kurzbezeichnung":"CWS-SoTiSaR","Studientitel":"Register für Weichteilsarkome und andere seltene Weichteiltumore bei Kindern, Jugendlichen und jungen Erwachsenen","Status":"active","Phase":null,"Organsystem":"Mesotheliales Gewebe und Weichteilgewebe","Organsystem_Alias":"weichteilgewebe","Molekulare Marker":null,"Histologischer Typ":"Weichteilsarkom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Patrick Hundsdörfer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Deutsche Kinderkrebs Stiftung","Studienbeginn":"2009-07-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C487"},{"Studiencode":"20260615C488","Studiencode_Anzeige":null,"Kurzbezeichnung":"Informativer Charité Patient (ICP)","Studientitel":"Longitudinale Erhebung von Patienten- und Tumorcharakteristika bei Patienten mit gastrointestinalem Malignom mit einer Indikation zur Systemtherapie","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-05-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C488"},{"Studiencode":"20260615C489","Studiencode_Anzeige":null,"Kurzbezeichnung":"In vitro Charakterisierung Leber (EA1/353/16)","Studientitel":"In vitro Charakterisierung von Lymphozyten der angeborenen Immunantwort in gesunden und maligne entartetem Lebergewebe und deren Wechselwirkung mit Tumorstammzellen und ausdifferenzierten Tumorzellen","Status":"active","Phase":null,"Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Klinik für Allgemein- und Viszeralchirurgie","PI":"Univ. Prof. Dr. rer. nat. Katja Kotsch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C489"},{"Studiencode":"20260615C490","Studiencode_Anzeige":null,"Kurzbezeichnung":"In vitro Charakterisierung Magen (EA1/269/20)","Studientitel":"In vitro Charakterisierung von Lymphozyten und Organoidherstellung aus humanem Magengewebe","Status":"active","Phase":null,"Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Klinik für Allgemein- und Viszeralchirurgie","PI":"Univ.-Prof. Dr. Katja Kotsch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C490"},{"Studiencode":"20260615C493","Studiencode_Anzeige":null,"Kurzbezeichnung":"BYP Register (Berlin Young Patients)","Studientitel":"Register für Brustkrebs vor dem 40. Lebensjahr - Um die Besonderheiten von Brustkrebs und Brustkrebsvorstufen (DCIS) junger Frauen besser verstehen zu können, untersucht das BYP-Register klinische Daten, Biomaterialien und Krankheitsverläufe. Ziel des BYP-Registers ist es Grundlagen für eine altersspezifische Beratung und Nachsorge junger Frauen mit Brustkrebserkrankungen und Brustkrebsvorstufen (DCIS) zu ermöglichen.","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. Maria Margarete Karsten","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C493"},{"Studiencode":"20260615C494","Studiencode_Anzeige":null,"Kurzbezeichnung":"INTEGRATE-ATMP","Studientitel":"Integrierte Versorgung Neuer Therapien durch Telemedizin, Empowerment, Gentherapeutika, Registeretablierung, Arzneimittelsicherheit, Therapiepfaden und Erstattung","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Olaf Penack","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Heidelberg","Studienbeginn":"2023-02-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C494"},{"Studiencode":"20260615C496","Studiencode_Anzeige":null,"Kurzbezeichnung":"EU-RHAB Register","Studientitel":"EUROPEAN RHABDOID REGISTRY A multinational registry for rhabdoid tumors of any anatomical site","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Weichteilsarkom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Augsburg","Studienbeginn":"2010-07-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C496"},{"Studiencode":"20260615C498","Studiencode_Anzeige":null,"Kurzbezeichnung":"Rare tumors (RT, RT-MORAT, RT-ExTTrare)","Studientitel":"Preclinical models for rare tumors to advance precision oncology development","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Jun.-Prof. Dr. Ana Pestana","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-05-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C498"},{"Studiencode":"20260615C499","Studiencode_Anzeige":null,"Kurzbezeichnung":"ALL-REZ BFM-Beobachtungsstudie","Studientitel":"ALL-REZ BFM-Beobachtungsstudie und Biobank für Rezidive einer akuten lymphoblastischen Leukämie im Kindes – und Jugendalter","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Deutsche Kinderkrebs Stiftung","Studienbeginn":"2012-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C499"},{"Studiencode":"20260615C500","Studiencode_Anzeige":null,"Kurzbezeichnung":"HULU Projekt","Studientitel":"Pathogen-induzierte Aktivierung humaner Lungen, Analyse von Lungengewebeproben;Studie mit wissenschaftlicher feingeweblicher und biochemischer Untersuchung","Status":"active","Phase":null,"Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"Karzinom, NSCLC","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Allgemein- und Viszeralchirurgie","PI":"Prof. Dr. med. Jens Neudecker","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2009-11-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C500"},{"Studiencode":"20260615C501","Studiencode_Anzeige":null,"Kurzbezeichnung":"AG PenisCa","Studientitel":"Prospektive Kohortenanalyse des Peniskarzinoms – einer der seltensten Tumorentitäten in Deutschland","Status":"active","Phase":null,"Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Dr. med. Maximilian Reimann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-11-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C501"},{"Studiencode":"20260615C502","Studiencode_Anzeige":null,"Kurzbezeichnung":"TMS-Studie","Studientitel":"Nicht-invasive Klärung der funktionellen Anatomie bei eloquent lokalisierten Läsionen mittels navigierter transkranieller Magnetstimulation - Diagnostische Studie","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"Prof. Dr. Thomas Picht","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2012-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C502"},{"Studiencode":"20260615C503","Studiencode_Anzeige":null,"Kurzbezeichnung":"Gesundheitskompetenz von Patientinnen in der gynäko-onkologischen Nachsorge","Studientitel":"Gesundheitskompetenz von Patientinnen in der gynäko-onkologischen Nachsorge","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"weibliche genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Dr. med. Hannah Woopen, MSc","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C503"},{"Studiencode":"20260615C504","Studiencode_Anzeige":null,"Kurzbezeichnung":"AML-BFM 2012 Register","Studientitel":"AML-BFM 2012 Register Erfassung der genetischen, molekulargenetischen und epigenetischen Charakteristika der AML bei Kindern und Jugendlichen","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"AML","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Hannover Medical School  (Hannover Medical School)","Studienbeginn":"2012-04-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C504"},{"Studiencode":"20260615C505","Studiencode_Anzeige":null,"Kurzbezeichnung":"NHL-BFM Registry 2012","Studientitel":"Registry of the NHL-BFM study group for all subtypes of Non-Hodgkin Lymphoma diagnosed in children and adolescents","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":null,"PI":"Dr. med. Andrej Lissat","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Giessen  (University of Giessen)","Studienbeginn":"2012-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C505"},{"Studiencode":"20260615C506","Studiencode_Anzeige":null,"Kurzbezeichnung":"Sexualität bei Langzeitüberlebenden mit Eierstockkrebs","Studientitel":"Sexualität bei Langzeitüberlebenden mit Eierstockkrebs","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"eierstock","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Dr. Hannah Woopen","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C506"},{"Studiencode":"20260615C507","Studiencode_Anzeige":null,"Kurzbezeichnung":"EUROPA","Studientitel":"EU RWE Study of 1L Maintenance Therapy in Ovarian Cancer Patients","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. med. Elena Ioana Braicu","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"GlaxoSmithKline  (GlaxoSmithKline)","Studienbeginn":"2024-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C507"},{"Studiencode":"20260615C508","Studiencode_Anzeige":null,"Kurzbezeichnung":"GPOH Lebertumorregister","Studientitel":"Register für Lebertumoren bei Kindern und Jugendlichen","Status":"active","Phase":null,"Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"leber","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Patrick Hundsdörfer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2011-11-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C508"},{"Studiencode":"20260615C510","Studiencode_Anzeige":null,"Kurzbezeichnung":"RB-registry (Retinoblastomregister)","Studientitel":"RB-registry: a clinical registry for prospective data on retinoblastoma epidemiology and clinical course","Status":"active","Phase":null,"Organsystem":"Auge","Organsystem_Alias":"auge","Molekulare Marker":null,"Histologischer Typ":"Retinoblastom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Madlen Reschke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Essen  (University of Essen)","Studienbeginn":"2013-11-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C510"},{"Studiencode":"20260615C511","Studiencode_Anzeige":null,"Kurzbezeichnung":"Ped-PTLD Register","Studientitel":"Lymphoproliferative Erkrankungen nach Organtransplantation im Kindesalter (PTLD)","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. Dr. Karl Seeger","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2014-01-02 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C511"},{"Studiencode":"20260615C512","Studiencode_Anzeige":null,"Kurzbezeichnung":"ImmuMITT 2.0","Studientitel":"Longitudinal immunologic effects of cTACE in unresectable hepatocellular carcinoma – the prospective ImmuMITT 2.0 trial (Pilot study)","Status":"active","Phase":null,"Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie)","PI":"Priv.-Doz. Dr. med. Lynn Jeanette Savic","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-07-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C512"},{"Studiencode":"20260615C513","Studiencode_Anzeige":null,"Kurzbezeichnung":"68284528MMY4009 (MMY4009/CARTITUDE-P9)","Studientitel":"Eine Unbedenklichkeitsstudie nach der Zulassung zur Beurteilung der Sicherheit von Patienten mit multiplem Myelom, die mit Ciltacabtagen-Autoleucel behandelt werden","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":null,"Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Stephan Bohl","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Janssen Research & Development, LLC","Studienbeginn":"2025-10-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C513"},{"Studiencode":"20260615C514","Studiencode_Anzeige":null,"Kurzbezeichnung":"TOC-Studie","Studientitel":"Tumor Bank Ovarian Cancer Network","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. Elena Braicu","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2014-12-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C514"},{"Studiencode":"20260615C518","Studiencode_Anzeige":null,"Kurzbezeichnung":"LCH-REG-DE 2013","Studientitel":"Deutsches Register für Langerhanszell Histiozytosen im Kindes- und Jugendalter","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Langerhanszell Histiozytosen","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Frankfurt  (University of Frankfurt)","Studienbeginn":"2015-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C518"},{"Studiencode":"20260615C519","Studiencode_Anzeige":null,"Kurzbezeichnung":"rnTMS-Therapie-Studie (TMS-EEG)","Studientitel":"Repetitive navigierte transkranielle Magnetstimulation (rnTMS) als ergänzende Therapieoption für Patienten mit neu aufgetretener bzw. progredienter Parese nach supratentorieller Tumorresektion.","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie","PI":"Prof. Dr. Thomas Picht","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2016-02-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C519"},{"Studiencode":"20260615C520","Studiencode_Anzeige":null,"Kurzbezeichnung":"NOGGO RU1 (REGSA Sarkom-Register)","Studientitel":"Deutsches prospektives Register zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine.","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"weibliche genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. med. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C520"},{"Studiencode":"20260615C523","Studiencode_Anzeige":null,"Kurzbezeichnung":"CPT-SIOP-Register","Studientitel":"CPT-SIOP-Register (Choroid-Plexus-Tumore)","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"gehirn","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Deutsche Kinderkrebs Stiftung","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C523"},{"Studiencode":"20260615C525","Studiencode_Anzeige":null,"Kurzbezeichnung":"HIT-REZ-REGISTER","Studientitel":"Multinationales multizentrisches Register für Kinder, Jugendliche und junge Erwachsene mit therapierefraktären, progredienten oder rezidivierten Medulloblastomen, Pineoblastomen, primitiv neuroektodermalen Tumoren des ZNS (ZNS-PNETs) und Ependymomen","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"zns","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":null,"PI":"PD Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C525"},{"Studiencode":"20260615C526","Studiencode_Anzeige":null,"Kurzbezeichnung":"INFORM Registry","Studientitel":"INFORM - INdividualized Therapy FOr Relapsed Malignancies in Childhood","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Andrej Lissat","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"DKFZ","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C526"},{"Studiencode":"20260615C527","Studiencode_Anzeige":null,"Kurzbezeichnung":"EWOG-SAA (Schwere Aplastische Anämie) 2010","Studientitel":"Genetische und immunologische Charakterisierung der schweren aplastischen Anämie (SAA) bei Kindern und Jugendlichen","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"Aplastische Anämie","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Annette Künkele","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Freiburg  (University of Freiburg)","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C527"},{"Studiencode":"20260615C528","Studiencode_Anzeige":null,"Kurzbezeichnung":"Seltene Tumoren-Register (STEP)","Studientitel":"Register zur Verbesserung der epidemiologischen und klinischen Erfassung von Kindern und Jugendlichen mit besonders seltenen Tumoren.","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":null,"PI":"Prof. Dr. Dr. Karl Seeger","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C528"},{"Studiencode":"20260615C529","Studiencode_Anzeige":null,"Kurzbezeichnung":"AArau-Studie","Studientitel":"A Phase IIB study of the tetramodal therapy of T2-T4 Nx MO bladder cancer with hyperthermia combined with chemoradiotherapy following TUR-BT","Status":"active","Phase":"Phase II","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. med. Pirus Ghadjar","Ansprechpartner_Name":null,"Ansprechpartner_Email":"yvonne.saewe@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Kantonsspital Aarau","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C529"},{"Studiencode":"20260615C530","Studiencode_Anzeige":null,"Kurzbezeichnung":"ENSAT-Register","Studientitel":"Europäisches Netzwerk für Nebennierentumoren","Status":"active","Phase":null,"Organsystem":"Endokrine Drüsen","Organsystem_Alias":"Endokrine Drüsen","Molekulare Marker":null,"Histologischer Typ":"Nebennierenkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik für Endokrinologie und Stoffwechselmedizin","PI":"Univ.-Prof. Dr. med. Knut Mai","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"DFG  (Deutsche Forschungsgemeinschaft)","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C530"},{"Studiencode":"20260615C531","Studiencode_Anzeige":null,"Kurzbezeichnung":"NB Registry 2016","Studientitel":"Register für Neugeborene, Säuglinge, Kinder, Jugendliche und Erwachsene mit neu diagnostizierten und/oder Rückfall von neuroblastischen Tumoren","Status":"active","Phase":null,"Organsystem":"Endokrine Drüsen","Organsystem_Alias":"nebenniere","Molekulare Marker":null,"Histologischer Typ":"Neuroblastom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. Patrick Hundsdörfer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2017-02-14 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C531"},{"Studiencode":"20260615C532","Studiencode_Anzeige":null,"Kurzbezeichnung":"NOGGO S15 (FraStroC)","Studientitel":"Entwicklung und prospektive Validierung eines Frailty Scores für chemotherapieassoziierte Toxizität bei fortgeschrittenem Eierstockkrebs","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"PD Dr. med. Radoslav Chekerov","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2018-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C532"},{"Studiencode":"20260615C533","Studiencode_Anzeige":null,"Kurzbezeichnung":"nTMS-PAED","Studientitel":"Anwendung der navigierten transkraniellen Magnetstimulation (nTMS) in der pädiatrischen Neurochirurgie","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":null,"PI":"Prof. Dr. Thomas Picht","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2017-08-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C533"},{"Studiencode":"20260615C535","Studiencode_Anzeige":null,"Kurzbezeichnung":"Mobilize Memory","Studientitel":"Untersuchung zur Mobilisierung von Immunzellen aus dem Knochenmark von Stammzellspendern und deren Schicksal im Transplantatempfänger nach Transplantation","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2016-07-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C535"},{"Studiencode":"20260615C536","Studiencode_Anzeige":null,"Kurzbezeichnung":"AML-BFM Register 2017","Studientitel":"Register zur Erfassung akuter myeloischer Leukämien bei Kinder und Jugendlichen","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"AML","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Arend von Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)","Studienbeginn":"2018-11-23 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C536"},{"Studiencode":"20260615C537","Studiencode_Anzeige":null,"Kurzbezeichnung":"NOGGO S18 (EMRISK)","Studientitel":"Development of a Risk Prediciton Model for Chemotherapy-induced Nausea and Vomiting","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. med. Dr. h.c. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V. (NOGGO)","Studienbeginn":"2019-05-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C537"},{"Studiencode":"20260615C539","Studiencode_Anzeige":null,"Kurzbezeichnung":"HELP-ER (ENGOT-ov47-TR/NOGGO-TR2)","Studientitel":"Retrospektive / Prospektive Studie zur Entwicklung des HELP-ER-Scores (verbesserter AGO-Score) anhand der Analyse / Identifizierung von Biomarkern wie HE4 + CA125 aus Blut und Tumorgewebeproben als prädiktive Methode für die Resektabilität bei rez. Ovarialkarzinom","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. Elena Braicu","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V. (NOGGO)","Studienbeginn":"2019-04-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C539"},{"Studiencode":"20260615C540","Studiencode_Anzeige":null,"Kurzbezeichnung":"Outnet-Studie","Studientitel":"Befragung zur gesundheitsbezogenen Lebensqualität","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Psychosomatik","PI":"Prof. Dr. med. Matthias Rose","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2019-10-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C540"},{"Studiencode":"20260615C541","Studiencode_Anzeige":null,"Kurzbezeichnung":"ILC-Register-Studie","Studientitel":"ILC-Register-Studie","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. Maria Margarete Karsten","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2019-01-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C541"},{"Studiencode":"20260615C542","Studiencode_Anzeige":null,"Kurzbezeichnung":"CTC AMNIS","Studientitel":"Phenotyping of circulating tumor cells using the AMNIS ImageStream platform","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Ingeborg Tinhofer-Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2018-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C542"},{"Studiencode":"20260615C543","Studiencode_Anzeige":null,"Kurzbezeichnung":"HypoFocal","Studientitel":"Fokale Strahlendosiseskalation bei Patienten mit primärem Prostatakarzinom (HypoFocal) - eine prospektive, multizentrische, nicht-randomisierte, 2-armige Studie / Translationales Begleitprojekt: PersoRad","Status":"active","Phase":"Phase II","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":null,"PI":"Priv.-Doz. Dr. med. Sebastian Zschaeck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Freiburg  (University of Freiburg)","Studienbeginn":"2020-01-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C543"},{"Studiencode":"20260615C546","Studiencode_Anzeige":null,"Kurzbezeichnung":"Organoid-Projekt","Studientitel":"An advanced organoid platform for modeling tumor microenvironment interactions in solid cancer","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Ingeborg Tinhofer-Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2020-01-14 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C546"},{"Studiencode":"20260615C549","Studiencode_Anzeige":null,"Kurzbezeichnung":"MNP Int-R","Studientitel":"Molecular Data Generation a Clinical Follow-up within the International Molecular Neuropathology Registry","Status":"active","Phase":null,"Organsystem":"ZNS","Organsystem_Alias":"gehirn","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"PD Dr. med. Arend Koch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"DKFZ","Studienbeginn":"2021-02-06 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C549"},{"Studiencode":"20260615C552","Studiencode_Anzeige":null,"Kurzbezeichnung":"OrgaPanK/OrgaPanCCC","Studientitel":"Establishing a series of primary and metastatic organoids for personalised therapies of pancreatic cancer","Status":"active","Phase":null,"Organsystem":"Pankreas","Organsystem_Alias":"Pankreas","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. Christopher Neumann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2021-10-26 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C552"},{"Studiencode":"20260615C553","Studiencode_Anzeige":null,"Kurzbezeichnung":"GPOH-HD Register","Studientitel":"Prospektives Register für Kinder und Jugendliche mit klassischem Hodgkin-Lymphom, nodulärem Lymphozyten-prädominanten Hodgkin-Lymphom (nLPHL) und rezidiviertem Hodgkin-Lymphom","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Hodgkin Lymphom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Nikola Hagedorn","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Deutsche Kinderkrebs Stiftung","Studienbeginn":"2021-01-05 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C553"},{"Studiencode":"20260615C554","Studiencode_Anzeige":null,"Kurzbezeichnung":"iEwingRegistry","Studientitel":"International Euro Ewing Registry","Status":"active","Phase":null,"Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"knochen","Molekulare Marker":null,"Histologischer Typ":"Ewing-Sarkom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Anne Flörcken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Essen  (University of Essen)","Studienbeginn":"2020-11-04 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C554"},{"Studiencode":"20260615C556","Studiencode_Anzeige":null,"Kurzbezeichnung":"ExLiquid","Studientitel":"Stellenwert von Flüssigbiopsien zur verbesserten personalisierten Therapieselektion und dem Monitoring des Krankheitsverlaufs","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. Ingeborg Tinhofer-Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-01-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C556"},{"Studiencode":"20260615C557","Studiencode_Anzeige":null,"Kurzbezeichnung":"KPS-Register (Krebsprädispositionssyndrom-Register - LFS-KPS-01)","Studientitel":"Li-Fraumeni-Syndrom-Krebs-Prädispositions-Syndrom-Register 01","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":null,"PI":"PD Dr. med. Hedwig Deubzer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Hannover Medical School  (Hannover Medical School)","Studienbeginn":"2022-02-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C557"},{"Studiencode":"20260615C559","Studiencode_Anzeige":null,"Kurzbezeichnung":"CAR-T-Fitness","Studientitel":"Identifizierung spezifischer Expressionsmarker als Vorhersage für eine erfolgreiche Expansion von T-Zellen für die adaptive T-Zell-Therapie","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2022-08-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C559"},{"Studiencode":"20260615C560","Studiencode_Anzeige":null,"Kurzbezeichnung":"CANDOID (BC/CRC)","Studientitel":"Establishment of representative 3D model systems of metastatic colon and breast cancer for rapid pharmacotyping (CANDOID)","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom, Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Prof. Dr. Ulrich Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2023-03-31 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C560"},{"Studiencode":"20260615C564","Studiencode_Anzeige":null,"Kurzbezeichnung":"TITAN3 (ICB)","Studientitel":"ICB-Studie - Immunphänotypisierung bei Tumorimmuntherapie-assoziierte neurologische Nebenwirkungen (TITAN3)","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Il-Kang Na","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-01-31 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C564"},{"Studiencode":"20260615C565","Studiencode_Anzeige":null,"Kurzbezeichnung":"PREVENT","Studientitel":"Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. med. Dr. med. (syr) Mustafa Zelal Muallem","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Davol Inc.","Studienbeginn":"2024-07-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C565"},{"Studiencode":"20260615C566","Studiencode_Anzeige":null,"Kurzbezeichnung":"Baseline characterization of immune checkpoints","Studientitel":"Baseline characterization of immune checkpoints in unresectable hepatocellular carcinoma patients – Cohort trial","Status":"active","Phase":null,"Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie)","PI":"Priv.-Doz. Dr. med. Lynn Jeanette Savic","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-07-29 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C566"},{"Studiencode":"20260615C567","Studiencode_Anzeige":null,"Kurzbezeichnung":"Myelom-Register","Studientitel":"Langzeit-Beobachtung von PatientInnen mit Multiplem Myelom und dessen prämalignen Vorstufenerkrankungen","Status":"active","Phase":null,"Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Igor-Wolfgang Blau","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"German Speaking Myeloma Multicenter Group (GMMG)","Studienbeginn":"2024-12-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C567"},{"Studiencode":"20260615C568","Studiencode_Anzeige":null,"Kurzbezeichnung":"SURVIVE","Studientitel":"Prospektive, zweiarmig randomisierte, teilverblindete Studie zum Vergleich der Standard-Nachsorge mit intensivierter Nachsorge bei Brustkrebspatientinnen im Frühstadium","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Dr. med. Caroline Neeb","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Ulm","Studienbeginn":"2024-07-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C568"},{"Studiencode":"20260615C569","Studiencode_Anzeige":null,"Kurzbezeichnung":"Register Seltene Histiocytosen","Studientitel":"Register-Studie als Teil des LCH-Registers Deutschland - für die Weitergabe an das International Rare Histiocytic Disorders Registry (IRHDR)","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Langerhanszell Histiozytosen","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Dr. med. Susanne Holzhauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Rostock","Studienbeginn":"2025-01-31 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C569"},{"Studiencode":"20260615C570","Studiencode_Anzeige":null,"Kurzbezeichnung":"Seltene Tumoren-Register (STEP 2.0)","Studientitel":"Register zur Verbesserung der epidemiologischen und klinischen Erfassung von Kindern und Jugendlichen mit besonders seltenen Tumoren","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. med. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Universitätsklinikum Tübingen  (Universitätsklinikum Tübingen)","Studienbeginn":"2024-02-29 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C570"},{"Studiencode":"20260615C571","Studiencode_Anzeige":null,"Kurzbezeichnung":"LYMPH-CHECK","Studientitel":"Bessere Früherkennung von Brustlymphödem nach Brustkrebs mithilfe eines Patientinnen-Fragebogens","Status":"active","Phase":null,"Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. med. Maria Margarete Karsten","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2024-10-16 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C571"},{"Studiencode":"20260615C573","Studiencode_Anzeige":null,"Kurzbezeichnung":"proCTC","Studientitel":"Proliferation von zirkulierenden Tumorzellen für die personalisierte Behandlung von Tumorpatienten","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Prof. Dr. med. Ulrich Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2025-01-27 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C573"},{"Studiencode":"20260615C574","Studiencode_Anzeige":null,"Kurzbezeichnung":"ROSALIND","Studientitel":"Analyzing exceptional long-term survival in patients with poor prognosis solid tumors","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Prof. Dr. med. Ulrich Keilholz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Cure51","Studienbeginn":"2025-05-14 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260615C574"},{"Studiencode":"20023293","Studiencode_Anzeige":"20023293","Kurzbezeichnung":"Radiomics","Studientitel":"A whole body Radiomics approach in patients with metastatic melanoma undergoing systemic therapy: Fully automated longitudinal segmentation and Deep Learning-based outcome prediction","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Thomas Eigentler; Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20023293"},{"Studiencode":"3001114","Studiencode_Anzeige":"3001114","Kurzbezeichnung":"EA1/089/17 EKG Port+PICC","Studientitel":"Analyse der Machbarkeit der Katheterspitzenpositionierung von zentralvenösen Zugängen (z.B. Port-Katheter/peripher inserierter zentral-venöser Katheter (PICC)) anhand von EKG Veränderungen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"Prof. Dr. Bernhard Gebauer; PD Dr. Dr. Georg Böning","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001114"},{"Studiencode":"20024548","Studiencode_Anzeige":"20024548","Kurzbezeichnung":"IMA 203-301","Studientitel":"A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine  IMA203-301)","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"HLA","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Fortgeschritten","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024548"},{"Studiencode":"3000528","Studiencode_Anzeige":"3000528","Kurzbezeichnung":"BioBankHaut","Studientitel":"Klinisches Register und Biobanking in der Dermatologie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Thomas Eigentler; Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000528"},{"Studiencode":"3001118","Studiencode_Anzeige":"3001118","Kurzbezeichnung":"EA4/089/17 AL retro","Studientitel":"Retrospektive Analyse der Effektivität und Komplikationen der CT-gestützten Hochdosisbrachytherapie im Afterloadingverfahren im Rahmen der onkologischen Therapieroutine","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"PD Dr. Dr. Georg Böning; Prof. Dr. Bernhard Gebauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001118"},{"Studiencode":"3001115","Studiencode_Anzeige":"3001115","Kurzbezeichnung":"EA2/071/19 SIRT ADC","Studientitel":"Retrospektive Evaluation der multiparametrischen MRT zur Outcomebeurteilung/-prädiktion nach selektiver, interner Radioembolisation (SIRT) bei hepatozellulärem Karzinom (HCC)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"Sonstiges","Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"Prof. Dr. Bernhard Gebauer; PD Dr. Dr. Georg Böning","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001115"},{"Studiencode":"20024530","Studiencode_Anzeige":"20024530","Kurzbezeichnung":"Speichelanalysen KHT","Studientitel":"Wissenschaftliche Untersuchungen von Speichelproben von Patientinnen und Patienten mit Kopf-Hals-Tumoren","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":"Sequenzierungspanel;Sonstiges","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"Dr. Dr. Elena Hofmann; Dr. Dr. Elena Hofmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024530"},{"Studiencode":"20011677","Studiencode_Anzeige":"20011677","Kurzbezeichnung":"RESCUE","Studientitel":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine SensitiveBreast Cancer (RESCUE)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"mamma","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Brustzentrum der Charité CCM","PI":"Prof. Dr. Jens-Uwe Blohmer; Prof. Dr. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20011677"},{"Studiencode":"3000874","Studiencode_Anzeige":"3000874","Kurzbezeichnung":"ALL-SZT","Studientitel":"ALL SCT FORUM Registry 2022 Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend Stackelberg; Prof. Dr. med. Arend Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000874"},{"Studiencode":"20022165","Studiencode_Anzeige":"20022165","Kurzbezeichnung":"CONNECT","Studientitel":"Verbunden in Isolation – Entwicklung und Machbarkeitsstudie einer digitalen Gruppenintervention zum Umgang mit Belastungen während der protektiven Isolation im Rahmen einer allogenen Stammzelltransplantation","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"karl.haller@charite.de;   karl.haller@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20022165"},{"Studiencode":"3000652","Studiencode_Anzeige":"3000652","Kurzbezeichnung":"PROTECT Charité","Studientitel":"Prostatakrebs-Screening mittels kurzer, kontrastmittelfreier Kernspintomographie der Prostata","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"prostata","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"PD Dr. Federico Collettini; PD Dr. Federico Collettini","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000652"},{"Studiencode":"3001461","Studiencode_Anzeige":"3001461","Kurzbezeichnung":"DENCUP","Studientitel":"Dosiseskalierte und adaptive Radiochemotherapie für irresektable Pankreaskarzinome","Status":"active","Phase":"Phase I","Organsystem":"Pankreas","Organsystem_Alias":"pankreas","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"PD Dr. med. Sebastian Zschaeck; PD Dr. med. Sebastian Zschaeck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001461"},{"Studiencode":"20016035","Studiencode_Anzeige":"20016035","Kurzbezeichnung":"CELESTIAL","Studientitel":"Clinical Experience with Letermovir for CMV-Prophylaxis in Hemato-oncological Patients (CELESTIAL)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. med. Olaf Penack; Prof. Dr. med. Olaf Penack","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20016035"},{"Studiencode":"3000900","Studiencode_Anzeige":"3000900","Kurzbezeichnung":"Eva-IPPS","Studientitel":"Pilotierung einer Interdisziplinären Psychoonkologie/Palliativ-Sprechstunde (IPPS) in einer universitären Hochschulambulanz - eine prospektive Evaluations- und Machbarkeitsstudie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"karl.haller@charite.de;   karl.haller@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000900"},{"Studiencode":"20024364","Studiencode_Anzeige":"20024364","Kurzbezeichnung":"SLxxxxx","Studientitel":"Treatment reality and long-term outcome of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma - Results from a German real-world cohort and characterization of patients","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"leber","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hepatologie und Gastroenterologie CVK","PI":"Dr. med. univ. Raphael Mohr; Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024364"},{"Studiencode":"3001478","Studiencode_Anzeige":"3001478","Kurzbezeichnung":"RLT-genetics","Studientitel":"Genetische Alterationen bei Prostatakarzinom-Patienten unter Radioligandentherapie mit Lu-177-PSMA: Eine retrospektive Analyse","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"prostata","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Arbeitsbereich Klinische Nuklearmedizin - CVK","PI":"Dr. med. Markus Galler; Dr. med. Markus Galler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001478"},{"Studiencode":"20013117","Studiencode_Anzeige":"20013117","Kurzbezeichnung":"FACTS","Studientitel":"FACTS study Feasibility and acceptability of a cervical HPV and dysplasia testing and triaging using self-sampling.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"zervix","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie CBF - ALT","PI":"PD Dr. rer. nat Andreas Kaufmann; PD Dr. rer. nat Andreas Kaufmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20013117"},{"Studiencode":"3000664","Studiencode_Anzeige":"3000664","Kurzbezeichnung":"CAR-T solide Tumoren","Studientitel":"Mononukleäre Zellen zur Immuntherapie: Verwendung mononukleärer Zellen zur Generierung von Chimären Antigen Rezeptor (CAR) tragenden T Zellen für die präklinische Charakterisierung und Optimierung zur Behandlung von soliden Tumoren","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Institut für Pathologie CCM/CVK","PI":"Prof. Dr. David Horst; Prof. Dr. David Horst","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000664"},{"Studiencode":"3001509","Studiencode_Anzeige":"3001509","Kurzbezeichnung":"KI-CL","Studientitel":"Künstliche Intelligenz (KI)-gestützte histologische Diagnostik bei kutanen Lymphome","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"CD3","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Dr. med. Rose Moritz; Dr. med. Rose Moritz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001509"},{"Studiencode":"20012677","Studiencode_Anzeige":"20012677","Kurzbezeichnung":"Niraparib CUP","Studientitel":"German evaluation of niraparib in Clinical Practice An evaluation of clinical experience during the Compassionate Use Program (CUP) in Germany","Status":"active","Phase":"Phase IV","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"eierstock","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie CVK","PI":"Univ.-Prof. Dr. Jalid Sehouli; Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20012677"},{"Studiencode":"3000196","Studiencode_Anzeige":"3000196","Kurzbezeichnung":"Precare-FACTS","Studientitel":"PREdicting Cervical Abnormalities and Regression (Precare). Stage 1: Cross validation of Cervical Cancer Screening assays","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"zervix","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie CVK","PI":"PD Dr. rer. nat Andreas Kaufmann; PD Dr. rer. nat Andreas Kaufmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000196"},{"Studiencode":"3000979","Studiencode_Anzeige":"3000979","Kurzbezeichnung":"Kon-Track","Studientitel":"Kon-Track: Analyse von Häufigkeit und Anlass von stationären Kontakten zwischen Patientinnen mit Ovarialkarzinom und Krankenhauspersonal mit Fokus auf Pflegefachpersonen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"eierstock","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie CVK","PI":"julia.klews@charite.de;   julia.klews@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000979"},{"Studiencode":"20024232","Studiencode_Anzeige":"20024232","Kurzbezeichnung":"mp-HNSCC","Studientitel":"Untersuchung von Metastasierungsprädiktoren bei Kopf-Hals-Plattenepithelkarzinomen und deren cervikalen Metastasen durch Magnetresonanz-Elastographie und multiparametrischen Ultraschall","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Hals-, Nasen-, Ohrenheilkunde CCM","PI":"Dr. med. Katharina Margherita Wakonig; Dr. med. Katharina Margherita Wakonig","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024232"},{"Studiencode":"3000567","Studiencode_Anzeige":"3000567","Kurzbezeichnung":"Kopf-Hals-Tumoren","Studientitel":"Retrospektive Auswertung von Tumoren im Kopf-Hals-Bereich","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"PD Dr. Dr. Jan Voß; PD Dr. Dr. Jan Voß","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000567"},{"Studiencode":"3001651","Studiencode_Anzeige":"3001651","Kurzbezeichnung":"PETCT/PETMRT","Studientitel":"Vergleich der diagnostischen Genauigkeit der FDG-PET/CT vs. FDG-PET/MRT bei Patienten_innen mit Verdacht auf ein Rezidiv eines oralen Plattenepithelkarzinoms","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Mundhöhle","Organsystem_Alias":"mundhöhle","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"PD Dr. Dr. Christian Doll; PD Dr. Dr. Christian Doll","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001651"},{"Studiencode":"20017003","Studiencode_Anzeige":"20017003","Kurzbezeichnung":"MMS","Studientitel":"Indikationsstellung zur operativen Therapie von Wirbelsäulenmanifestationen des Muliplen Myeloms","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Neurochirurgie CCM","PI":"PD Dr. med. Julia Onken; PD Dr. med. Julia Onken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017003"},{"Studiencode":"3000440","Studiencode_Anzeige":"3000440","Kurzbezeichnung":"Registerstudie SRS","Studientitel":"Prospektive Registerstudie zur Erfassung von in der klinischen Routine am Cyberknife gewonnenen Patientendaten für zukünftige Datenanalysen (mit retrospektivem Anteil)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Neurochirurgie CCM","PI":"Prof. Dr. Peter Vajkoczy; PD Dr. med. Güliz Acker","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000440"},{"Studiencode":"3000568","Studiencode_Anzeige":"3000568","Kurzbezeichnung":"EPI","Studientitel":"Untersuchung des Auftretens einer exokrinen Pankreas-Insuffizienz und Graft-versus-Host-Reaktion im Bereich des Darms und Pankreas nach Stammzelltransplantation im Kindes- und Jugendalter","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Pankreas","Organsystem_Alias":"pankreas","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Michael Launspach; Dr. med. Michael Launspach","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000568"},{"Studiencode":"20020580","Studiencode_Anzeige":"20020580","Kurzbezeichnung":"COMFORT","Studientitel":"COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Harnorgane","Organsystem_Alias":"harnorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CBF","PI":"Dr. med. Keno Bressem; Dr. med. Keno Bressem","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20020580"},{"Studiencode":"3000062","Studiencode_Anzeige":"3000062","Kurzbezeichnung":"ZHEAbdTu","Studientitel":"Studie zur Anwendung der zeitharmonischen Elastographie für die nicht-invasive Charakterisierung von Tumoren im Abdomen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CCM","PI":"PD Dr. med. Stephan Rodrigo Marticorena Garcia; PD Dr. med. Stephan Rodrigo Marticorena Garcia","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000062"},{"Studiencode":"3000063","Studiencode_Anzeige":"3000063","Kurzbezeichnung":"ZHEKoHaTu","Studientitel":"Studie zur Anwendung der zeitharmonischen Elastographie für die nicht-invasive Charakterisierung von Kopf-Halstumoren","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CCM","PI":"PD Dr. med. Stephan Rodrigo Marticorena Garcia; PD Dr. med. Stephan Rodrigo Marticorena Garcia","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000063"},{"Studiencode":"20022413","Studiencode_Anzeige":"20022413","Kurzbezeichnung":"FOR 5628-C01","Studientitel":"C01 Multiskalige mechanische Eigenschaften von Tumoren und Tumorumgebung - von Gewebeproben zu Patienten","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CCM","PI":"PD Dr. med. Stephan Rodrigo Marticorena Garcia; PD Dr. med. Stephan Rodrigo Marticorena Garcia","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20022413"},{"Studiencode":"3001685","Studiencode_Anzeige":"3001685","Kurzbezeichnung":"IRON II","Studientitel":"Prospektive Evaluation des Einflusses des Eisenhaushalts und eisendefizienz-bedingter Anämie auf die Lebensqualität und die körperliche Belastbarkeit von Patient:innen, die sich einer kurativ intendierten Radiochemotherapie unterziehen (IRON II)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001685"},{"Studiencode":"3000504","Studiencode_Anzeige":"3000504","Kurzbezeichnung":"MAMRAD","Studientitel":"MAMRAD","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"mamma","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Dr. Felix Mehrhof; Dr. Felix Mehrhof","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000504"},{"Studiencode":"3000470","Studiencode_Anzeige":"3000470","Kurzbezeichnung":"RT-Sarcoma","Studientitel":"Die Rolle der Strahlentherapie in der multimodalen Behandlung von Sarkomen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Mesotheliales Gewebe und Weichteilgewebe","Organsystem_Alias":"weichteilgewebe","Molekulare Marker":null,"Histologischer Typ":"Weichteilsarkom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"PD Dr. David Kaul; PD Dr. David Kaul","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000470"},{"Studiencode":"20017835","Studiencode_Anzeige":"20017835","Kurzbezeichnung":"MDC_CAR_CXCR5","Studientitel":"A phase I trial to establish the safety and maximum tolerated dose of MDC_CAR_CXCR5_001 targeting CXCR5 in relapsed/refractory B-NHL patients","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Ulrich Keller; Prof. Dr. Ulrich Keller","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017835"},{"Studiencode":"20017468","Studiencode_Anzeige":"20017468","Kurzbezeichnung":"Hemoscreen","Studientitel":"Hemoscreen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"kolon","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. Anne Flörcken; Prof. Dr. Anne Flörcken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017468"},{"Studiencode":"3000689","Studiencode_Anzeige":"3000689","Kurzbezeichnung":"Mangiare","Studientitel":"Mangire = Modified additional Nutrition in Gastro-Intestinal Adenocarcinoma prior Resection – Evaluation - Studie zur Evaluation der biologischen Effekte von drei verschiedenen Ernährungsszenarien bei Patient*innen mit Tumoren des oberen gastrointestinalen Traktes unter kurativ intendierter multimodaler Therapie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"oberer gi-trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"peter.thuss@charite.de;   peter.thuss@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000689"},{"Studiencode":"3000727","Studiencode_Anzeige":"3000727","Kurzbezeichnung":"UrOrg","Studientitel":"Etablierung einer Organoidbiobank zur Erforschung urologischer Tumorerkrankungen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Harnorgane","Organsystem_Alias":"harnorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Urologie CCM","PI":"Dr. rer. nat. Annika Fendler; Dr. rer. nat. Annika Fendler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000727"},{"Studiencode":"3000850","Studiencode_Anzeige":"3000850","Kurzbezeichnung":"HEMIPEL","Studientitel":"Onkologisches und funktionelles Outcome nach interner Hemipelvektomie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"knochen","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Centrum für Muskuloskeletale Chirurgie (CMSC) CVK","PI":"Dr. med. Silvan Wittenberg; Dr. med. Silvan Wittenberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000850"},{"Studiencode":"3000188","Studiencode_Anzeige":"3000188","Kurzbezeichnung":"MR Rektumkarzinom","Studientitel":"Lokoregionäres Staging des Rektumkarzinoms mittels quantitativer multiparametrischer Magnetresonanztomografie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"rektosigmoid","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Allgemein-, Viszeral- und Gefäßchirurgie CBF","PI":"PD Dr. Florian Nino Loch; PD Dr. Florian Nino Loch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000188"},{"Studiencode":"3000739","Studiencode_Anzeige":"3000739","Kurzbezeichnung":"Liquid Biopsy","Studientitel":"Wissenschaftliche Untersuchungen von Gewebe- und Blutproben von Patientinnen und Patienten mit Kopf-Hals-Tumoren","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"Prof. Dr. Dr. Max Heiland; Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000739"},{"Studiencode":"3000584","Studiencode_Anzeige":"3000584","Kurzbezeichnung":"Pull through","Studientitel":"Modification of the pull-through technique using a v-shaped osteotomy in the resection of posterior tongue carcinomas. A pilot study.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Mundhöhle","Organsystem_Alias":"zunge","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"PD Dr. Dr. Steffen Koerdt; PD Dr. Dr. Steffen Koerdt","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000584"},{"Studiencode":"3000571","Studiencode_Anzeige":"3000571","Kurzbezeichnung":"Spinale Metastasen","Studientitel":"Retrospektives Spinale Metastasen Register","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"knochen","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Neurochirurgie CCM","PI":"Dr. med. Vanessa Hubertus; Dr. med. Vanessa Hubertus","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000571"},{"Studiencode":"3000800","Studiencode_Anzeige":"3000800","Kurzbezeichnung":"RBWW","Studientitel":"Evaluation der Erkrankungs- und Therapielast von an Retinoblastom erkrankten Kindern und deren Familien.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Auge","Organsystem_Alias":"auge","Molekulare Marker":null,"Histologischer Typ":"Retinoblastom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Madlen Reschke; Dr. med. Madlen Reschke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000800"},{"Studiencode":"20015896","Studiencode_Anzeige":"20015896","Kurzbezeichnung":"CIEMAR","Studientitel":"CIRSE Emprint Microwave Ablation Registry","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"Prof. Dr. Bernhard Gebauer; Prof. Dr. Bernhard Gebauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20015896"},{"Studiencode":"20016798","Studiencode_Anzeige":"20016798","Kurzbezeichnung":"ALXN1210-TMA-313","Studientitel":"A Phase 3, Open-Label, Randomized, Multi-Center Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. med. Olaf Penack; Prof. Dr. med. Olaf Penack","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20016798"},{"Studiencode":"3001466","Studiencode_Anzeige":"3001466","Kurzbezeichnung":"VALSE","Studientitel":"Deutsche Übersetzung und Validierung der Stanford Emotional Self-Efficacy Scale–Cancer (SESES-C) zur Erfassung der emotionalen Selbstwirksamkeit bei Krebspatient:innen [VALSE]","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"karl.haller@charite.de;   karl.haller@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001466"},{"Studiencode":"20024637","Studiencode_Anzeige":"20024637","Kurzbezeichnung":"Restalyst","Studientitel":"The role of ERBB3 and HCC-REAAD  diagnostic algorithm for the early detection of Hepatocellular Carcinoma","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"leber","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hepatologie und Gastroenterologie CVK","PI":"Dr. med. univ. Raphael Mohr; Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024637"},{"Studiencode":"06312137","Studiencode_Anzeige":"20023278","Kurzbezeichnung":"MK-2870-019","Studientitel":"A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"NSCLC","Therapiesetting":"Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06312137","EudraCT-Nr":"2023-508012-35-00","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2025-12-09 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06312137"},{"Studiencode":"20255217382700_2","Studiencode_Anzeige":"20023589","Kurzbezeichnung":"AVETUX-HN","Studientitel":"Eine randomisierte Phase-II-Studie zum Vergleich von zwei gegenüber vier Zyklen einer Kombinationstherapie mit Cetuximab, Avelumab, Cisplatin und Docetaxel bei Patientinnen und Patienten mit rezidiviertem, metastasiertem Kopf-Hals-Krebs","Status":"active","Phase":"Phase II","Organsystem":"Kopf-Hals","Organsystem_Alias":"Kopf-Hals","Molekulare Marker":"PD-1","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Konrad Klinghammer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-521738-27-00","Sponsor":"Charité","Studienbeginn":"2026-01-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255217382700_2"},{"Studiencode":"06127407","Studiencode_Anzeige":"3001981","Kurzbezeichnung":"CL3-95031-007","Studientitel":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants =18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen","Status":"active","Phase":"Phase III","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"IDH1","Histologischer Typ":"Chondrosarkom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":"1st line, 2nd line, 3rd line","Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Anne Flörcken","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06127407","EudraCT-Nr":"2023-508507-20-00","Sponsor":"Servier","Studienbeginn":"2025-07-22 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06127407"},{"Studiencode":"06112314","Studiencode_Anzeige":"20022526","Kurzbezeichnung":"IMC-F106C-301","Studientitel":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF, HLA-A","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT06112314","EudraCT-Nr":"2023-505306-42-00","Sponsor":"Immunocore Ltd, United Kingdom","Studienbeginn":"2024-09-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06112314"},{"Studiencode":"20245160783100","Studiencode_Anzeige":"20014420","Kurzbezeichnung":"rEECur","Studientitel":"International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma","Status":"active","Phase":"Phase II","Organsystem":"Knochen und Gelenkknorpel","Organsystem_Alias":"Knochen und Gelenkknorpel","Molekulare Marker":null,"Histologischer Typ":"Ewing-Sarkom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. Anne Flörcken; Prof. Dr. Anne Flörcken","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2014-000259-99","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245160783100"},{"Studiencode":"06119581","Studiencode_Anzeige":"20023140","Kurzbezeichnung":"J3M-MC-JZQB","Studientitel":"A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression =50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"KRAS","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06119581","EudraCT-Nr":"2023-503412-33-00","Sponsor":"Eli Lilly and Company","Studienbeginn":"2025-02-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06119581"},{"Studiencode":"06136650","Studiencode_Anzeige":"20022669","Kurzbezeichnung":"Omaha-004 MK-5684-00","Studientitel":"A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)","Status":"active","Phase":"Phase III","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":"Sonstiges","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":"3rd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis; Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06136650","EudraCT-Nr":"2023-504957-11","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2024-07-02 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06136650"},{"Studiencode":"05704829","Studiencode_Anzeige":"20021907","Kurzbezeichnung":"ADAPT-HER2-IV","Studientitel":"NeoAdjuvante, an Dynamischen Markern Adjustierte, Personalisierte Therapie mit Trastuzumab-Deruxtecan im Vergleich zu Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in frühem, HER2-positivem Brustkrebs","Status":"active","Phase":"Phase II","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"HER2","Histologischer Typ":"Karzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Dr. med. Caroline Neeb","Ansprechpartner_Name":null,"Ansprechpartner_Email":"brustzentrum-studienzentrum@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664485","ClinTrials.gov identifier":"NCT05704829","EudraCT-Nr":"2022-003865-39","Sponsor":"Westdeutsche Studiengruppe GmbH (WSG)","Studienbeginn":"2024-06-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05704829"},{"Studiencode":"04877522","Studiencode_Anzeige":"20017424","Kurzbezeichnung":"CABL001A2001B","Studientitel":"An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"Ph+","Histologischer Typ":"CML","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Philipp le Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 563","ClinTrials.gov identifier":"NCT04877522","EudraCT-Nr":"2021-000602-17","Sponsor":"Novartis Pharmaceuticals","Studienbeginn":"2022-12-21 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/04877522"},{"Studiencode":"3000106","Studiencode_Anzeige":"3000106","Kurzbezeichnung":"LB_HTCC_MEL","Studientitel":"Liquid Biopsy als Tumormarker im Rahmen der Therapie von Patienten mit einem fortgeschrittenen Melanom","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Kamran Ghoreschi; Dr. rer. nat. Franz Joachim Hilke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000106"},{"Studiencode":"06163430","Studiencode_Anzeige":"20022846","Kurzbezeichnung":"TERN-701 in CML","Studientitel":"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"BCR::ABL1","Histologischer Typ":"CML","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Philipp le Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 132","ClinTrials.gov identifier":"NCT06163430","EudraCT-Nr":"2023-507677-18-00","Sponsor":"Terns, Inc.","Studienbeginn":"2024-09-11 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06163430"},{"Studiencode":"06750094","Studiencode_Anzeige":"20024696","Kurzbezeichnung":"OrigAMI-3","Studientitel":"A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"BRAF, KRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06750094","EudraCT-Nr":"2024-513853-66-00","Sponsor":"Janssen Research & Development, LLC","Studienbeginn":"2025-04-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06750094"},{"Studiencode":"06662786","Studiencode_Anzeige":"20024083","Kurzbezeichnung":"OrigAMI-2","Studientitel":"A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"KRAS, NRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT06662786","EudraCT-Nr":"2024-513852-13-00","Sponsor":"Janssen Research & Development, LLC","Studienbeginn":"2025-02-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06662786"},{"Studiencode":"3001197","Studiencode_Anzeige":"3001197","Kurzbezeichnung":"pro-duct002","Studientitel":"Perihilar cholangiocarcinoma","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"gallengang","Molekulare Marker":null,"Histologischer Typ":"Gallengangskarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Chirurgische Klinik Campus Virchow-Klinikum","PI":"Prof. Dr. Johann Pratschke; Prof. Dr. Johann Pratschke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001197"},{"Studiencode":"3001304","Studiencode_Anzeige":"3001304","Kurzbezeichnung":"RESEX","Studientitel":"RESEX - Auswirkungen der multimodalen Rektum-Chirurgie auf die Anorektal-, Urogenital- und Sexualfunktion","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Allgemein-, Viszeral- und Gefäßchirurgie CBF","PI":"Prof. Dr. Johannes Lauscher; Prof. Dr. Johannes Lauscher","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001304"},{"Studiencode":"20013164","Studiencode_Anzeige":"20013164","Kurzbezeichnung":"AC1803","Studientitel":"Collection of viable lymph node tissue of DLBCL patients for function drug response and genomic profiling","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":null,"Histologischer Typ":"Diffus großzelliges B-Zell-Lymphom (DLBCL)","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Ulrich Keller; Prof. Dr. Ulrich Keller","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20013164"},{"Studiencode":"20245174322100","Studiencode_Anzeige":"20025221","Kurzbezeichnung":"BELLA","Studientitel":"A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","Status":"active","Phase":"Phase II","Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Metastasiert, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Univ.-Prof. Dr. Jalid Sehouli","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-517432-21-00","Sponsor":"Corcept Therapeutics","Studienbeginn":"2025-08-26 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245174322100"},{"Studiencode":"20245149173600","Studiencode_Anzeige":"20015669","Kurzbezeichnung":"HR-NBL2 (SIOPEN)","Studientitel":"Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma.","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Neuroblastom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. Angelika Eggert","Ansprechpartner_Name":null,"Ansprechpartner_Email":"egle.kievaite@charite.de","Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2019-001068-31","Sponsor":"Gustave Roussy, France","Studienbeginn":"2024-07-02 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245149173600"},{"Studiencode":"3001532","Studiencode_Anzeige":"3001532","Kurzbezeichnung":"PRE-KOVER I","Studientitel":"Prospektive Evaluation der Frailty bei Patient:innen mit Kopf-Hals Tumoren vor kurativ intendierter Therapie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001532"},{"Studiencode":"3001541","Studiencode_Anzeige":"3001541","Kurzbezeichnung":"RO_eHEalth","Studientitel":"Evaluation der Technologieakzeptanz und der digitalen Gesundheitskompetenz von Patient:innen, die sich einer Strahlentherapie unterziehen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001541"},{"Studiencode":"20019529","Studiencode_Anzeige":"20019529","Kurzbezeichnung":"Mikrokatheter-Studie","Studientitel":"Prospective study evaluating different microcatheter systems for intra-arterial therapies of hypervascularized liver tumors","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"leber","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radiologie (mit dem Bereich Kinderradiologie) - CVK","PI":"PD Dr. med. Lynn Jeanette Savic; PD Dr. med. Lynn Jeanette Savic","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20019529"},{"Studiencode":"20005383","Studiencode_Anzeige":"20005383","Kurzbezeichnung":"Versorgung HPN","Studientitel":"Erfassung der Versorgungssituation von Tumorpatienten mit/ohne Migrationshintergrund mit individueller parenteraler Ernährungstherapie/Compounding (heimparenteraler Ernährung (- HPN)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"peter.thuss@charite.de;   peter.thuss@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20005383"},{"Studiencode":"20016016","Studiencode_Anzeige":"20016016","Kurzbezeichnung":"SCP2","Studientitel":"SCP2 - Skin Classification Project: Smarte Algorithmen zur Unterstützung in der Melanomdiagnostik","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Kamran Ghoreschi; Prof. Dr. Kamran Ghoreschi","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20016016"},{"Studiencode":"201900372738","Studiencode_Anzeige":"20016072","Kurzbezeichnung":"MEN1611-02","Studientitel":"OPEN-LABEL, MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CA MUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS","Status":"active","Phase":"Phase I/II","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"kolon","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2019-003727-38","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/201900372738"},{"Studiencode":"20260706C964","Studiencode_Anzeige":null,"Kurzbezeichnung":"OvCancerSurv Immune","Studientitel":"Untersuchung von therapie- und altersassoziierten immunologischen Veränderungen bei Langzeitüberlebenden nach bzw. mit Eierstockkrebs","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. Mareike Frick","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2026-06-23 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C964"},{"Studiencode":"20009648","Studiencode_Anzeige":"20009648","Kurzbezeichnung":"CIC424C2301","Studientitel":"A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"PD Dr. med. Lena Oevermann; PD Dr. med. Lena Oevermann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20009648"},{"Studiencode":"05797168","Studiencode_Anzeige":"20024918","Kurzbezeichnung":"FONTANA","Studientitel":"A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors","Status":"active","Phase":"Phase I/II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose, Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. Elena Braicu","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT05797168","EudraCT-Nr":"2022-502576-23-00","Sponsor":"AstraZeneca","Studienbeginn":"2026-05-20 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05797168"},{"Studiencode":"202200288431","Studiencode_Anzeige":null,"Kurzbezeichnung":"SAGITTARIUS","Studientitel":"Intensity of chemotherapy after surgery determined by DNA detection in blood of patients with local colon cancer","Status":"active","Phase":"Phase II","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Sebastian Stintzing","Ansprechpartner_Name":null,"Ansprechpartner_Email":"portalambulanz@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 132","ClinTrials.gov identifier":null,"EudraCT-Nr":"2022-002884-31","Sponsor":"IFOM - Istituto Fondazione di Oncologia Molecolare ETS","Studienbeginn":"2025-05-22 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/202200288431"},{"Studiencode":"07284433","Studiencode_Anzeige":"20026208","Kurzbezeichnung":"AVC-203-01 (QUADvance)","Studientitel":"A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies","Status":"active","Phase":"Phase I/II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":"CD19, CD20","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Frederik Damm","Ansprechpartner_Name":null,"Ansprechpartner_Email":"inna.hoyer@charite.de","Ansprechpartner_Telefon":"'+49 30 450553844","ClinTrials.gov identifier":"NCT07284433","EudraCT-Nr":null,"Sponsor":"AvenCell Europe GmbH","Studienbeginn":"2026-01-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07284433"},{"Studiencode":"07227350","Studiencode_Anzeige":null,"Kurzbezeichnung":"PH-L19IL2TNFCOMB-04/24","Studientitel":"A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)","Status":"active","Phase":"Phase II","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Basalzellkarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT07227350","EudraCT-Nr":"2025-523229-16-00","Sponsor":"Philogen S.p.A.  (Philogen S.p.A.)","Studienbeginn":"2026-06-26 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07227350"},{"Studiencode":"02165397","Studiencode_Anzeige":null,"Kurzbezeichnung":"AIO-PAK-0424 (UNITEPANC)","Studientitel":"Interventional, prospective, multisite, proof-of-concept, single-arm trial, using organoids to predict efficacy of adjuvant treatment in resectable pancreatic cancer - the UNITEPANC trial of the AIO Pancreatic Cancer Group","Status":"active","Phase":"Phase I/II","Organsystem":"Pankreas","Organsystem_Alias":"Pankreas","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Christopher Neumann","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ana.pestana@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 132","ClinTrials.gov identifier":"NCT02165397","EudraCT-Nr":"2023-510490-34-00","Sponsor":"University of Ulm","Studienbeginn":"2026-04-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/02165397"},{"Studiencode":"06743126","Studiencode_Anzeige":null,"Kurzbezeichnung":"IMA203-301 (SUPRAME)","Studientitel":"A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF, HLA-A","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":"baerbel.hoellen@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06743126","EudraCT-Nr":null,"Sponsor":"Immatics Biotechnologies GmbH","Studienbeginn":"2026-03-03 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06743126"},{"Studiencode":"06831981","Studiencode_Anzeige":null,"Kurzbezeichnung":"ARO 2024-13","Studientitel":"Radiochemotherapy With Concomitant Deep Regional Hyperthermia in Locally Advanced Rectal Cancer. A Prospective, Randomized Phase III Trial.","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Prof. Dr. med. Pirus Ghadjar","Ansprechpartner_Name":null,"Ansprechpartner_Email":"yvonne.saewe@charite.de","Ansprechpartner_Telefon":"'+49 30 450 527318","ClinTrials.gov identifier":"NCT06831981","EudraCT-Nr":null,"Sponsor":"University of Erlangen","Studienbeginn":"2026-01-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06831981"},{"Studiencode":"20027321","Studiencode_Anzeige":"20027321","Kurzbezeichnung":"NUACRES NIS 01","Studientitel":"Eine nicht-interventionelle Studie zur Bewertung der Aktivierung des Immunsystems von Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium (ES-SCLC) während der Standard Erstlinien-Chemoimmuntherapie und bei Tumor-Progress","Status":"active","Phase":null,"Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 044","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Nucleic Acids to the Rescue GmbH (NUACRES®)","Studienbeginn":"2026-06-18 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20027321"},{"Studiencode":"06764875","Studiencode_Anzeige":"20025293","Kurzbezeichnung":"ARTEMIDE-Gastric01","Studientitel":"A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer","Status":"active","Phase":"Phase III","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":"PD-L1, HER2","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Priv.-Doz. Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":"inna.hoyer@charite.de","Ansprechpartner_Telefon":"'+49 30 450553844","ClinTrials.gov identifier":"NCT06764875","EudraCT-Nr":"2024-512583-57-00","Sponsor":"AstraZeneca","Studienbeginn":"2026-01-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06764875"},{"Studiencode":"20260706C1397","Studiencode_Anzeige":null,"Kurzbezeichnung":"REPOSA","Studientitel":"REcovery of POstoperative Sleep and wellbeing in patients with ovarian cAncer","Status":"active","Phase":null,"Organsystem":"Weibliche Genitalorgane","Organsystem_Alias":"Weibliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"PD Dr. med. Hannah Woopen","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2026-01-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1397"},{"Studiencode":"20260706C1455","Studiencode_Anzeige":null,"Kurzbezeichnung":"Projekt sKIn DKFZ","Studientitel":"Prospektive und multizentrische Datensammlung zur Entwicklung eines KI-basierten Assistenzsystems für die Hautkrebsdiagnostik","Status":"active","Phase":null,"Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":"Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"DKFZ","Studienbeginn":"2026-01-16 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1455"},{"Studiencode":"20260706C1515","Studiencode_Anzeige":null,"Kurzbezeichnung":"PEARL","Studientitel":"Langzeitbehandlung mit PARP-Inhibitoren von Patientinnen mit platinsensiblen Eierstock-/Eileiter-/Bauchfellkrebsrezidiv mit der Lebensqualität im Fokus","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"PD Dr. med. Hannah Woopen","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2026-01-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1515"},{"Studiencode":"03486873","Studiencode_Anzeige":"20027000","Kurzbezeichnung":"MK-3475-587 (KEYNOTE-587)","Studientitel":"A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab","Status":"active","Phase":"Phase III","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"baerbel.hoellen@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT03486873","EudraCT-Nr":"2022-501254-10-00","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2026-06-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/03486873"},{"Studiencode":"20260706C1543","Studiencode_Anzeige":null,"Kurzbezeichnung":"OnkoAware","Studientitel":"Analyse der Gesundheitskompetenz und Selbstwirksamkeit bei onkologischen Patientinnen und Patienten","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"PD Dr. rer. nat. Ute Goerling","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2025-04-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1543"},{"Studiencode":"20260706C1568","Studiencode_Anzeige":null,"Kurzbezeichnung":"AIO-LQ-0125ass (ICOG-STRESS)","Studientitel":"Evaluation of psychological stress as an influencing factor on the effectiveness and quality of life during therapy with immune checkpoint inhibitors","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Neurologie mit Experimenteller Neurologie","PI":"PD Dr. med. Petra Hühnchen","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marco.kanter@charite.de","Ansprechpartner_Telefon":"'+49 30 450 630 074","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Hannover Medical School  (Hannover Medical School)","Studienbeginn":"2026-01-02 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1568"},{"Studiencode":"20260706C1606","Studiencode_Anzeige":null,"Kurzbezeichnung":"GPOH-MET Register","Studientitel":"Register zur Erfassung maligner endokriner Tumoren im Kindes- und Jugendalter","Status":"active","Phase":null,"Organsystem":"Endokrine Drüsen","Organsystem_Alias":"endokrine drüsen","Molekulare Marker":null,"Histologischer Typ":"Neuroendokrin (NET and NEC)","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. med. Pablo Hernáiz Driever","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Magdeburg  (University of Magdeburg)","Studienbeginn":"2016-08-01 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1606"},{"Studiencode":"07314164","Studiencode_Anzeige":null,"Kurzbezeichnung":"CLIN-60000-467 (CaboLife)","Studientitel":"A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Neuroendokrin (NET and NEC)","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"Dr. med. Peter Steinhagen","Ansprechpartner_Name":null,"Ansprechpartner_Email":"susanne.steglich@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 779","ClinTrials.gov identifier":"NCT07314164","EudraCT-Nr":null,"Sponsor":"Ipsen Pharma GmbH","Studienbeginn":"2026-04-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07314164"},{"Studiencode":"20260706C1841","Studiencode_Anzeige":null,"Kurzbezeichnung":"MINT","Studientitel":"Mogamulizumab in einer nicht-interventionellen Studie zur Bewertung von Sicherheit und Therapieerfolg bei der Behandlung von Mykosis Fungoides und Sézary-Syndrom (MINT)","Status":"active","Phase":null,"Organsystem":"Haut","Organsystem_Alias":"haut","Molekulare Marker":null,"Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":null,"PI":null,"Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260706C1841"},{"Studiencode":"06246149","Studiencode_Anzeige":"20023822","Kurzbezeichnung":"Atom 2022","Studientitel":"Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)","Status":"active","Phase":"Phase III","Organsystem":"Auge","Organsystem_Alias":"Auge","Molekulare Marker":"HLA-A","Histologischer Typ":"Aderhautmelanom","Therapiesetting":"Erstdiagnose","Therapielinie":"1st line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Caroline Anna Peuker","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT06246149","EudraCT-Nr":"2023-510333-28-00","Sponsor":"EORTC  (EORTC)","Studienbeginn":"2025-02-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06246149"},{"Studiencode":"03686124","Studiencode_Anzeige":"20020679","Kurzbezeichnung":"IMA203-101","Studientitel":"Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"HLA-A","Histologischer Typ":"Karzinom","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT03686124","EudraCT-Nr":"2019-002370-31","Sponsor":"Immatics Biotechnologies GmbH","Studienbeginn":"2023-07-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/03686124"},{"Studiencode":"06380686","Studiencode_Anzeige":"20023908","Kurzbezeichnung":"HEAT","Studientitel":"Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"Kopf-Hals","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Metastasiert","Therapielinie":"Keine","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Konrad Klinghammer; PD Dr. med. Konrad Klinghammer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT06380686","EudraCT-Nr":null,"Sponsor":"Arbeitsgemeinschaft Internistische Onkologie (AIO)","Studienbeginn":"2025-03-19 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06380686"},{"Studiencode":"20235041413100","Studiencode_Anzeige":"20022039","Kurzbezeichnung":"Discuss IKF","Studientitel":"Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized lowintervention phase II trial of the AIO working groups breast cancer and quality of life","Status":"active","Phase":"Phase II","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"HER2, HR","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Metastasiert","Therapielinie":"Keine","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-504141-31-00","Sponsor":"IKF Klinische Krebsforschung GmbH","Studienbeginn":"2024-09-12 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235041413100"},{"Studiencode":"201600418039","Studiencode_Anzeige":"20017205","Kurzbezeichnung":"UMBRELLA SIOP RTSG","Studientitel":"All children, adolescents or young adults with a primary or relapsed renal tumour diagnosed in a participating SIOP-RTSG centre are eligible for inclusion in the SIOP 2016 UMBRELLA study.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Harnorgane","Organsystem_Alias":"niere","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie","PI":"Prof. Dr. Hedwig Deubzer; Prof. Dr. Hedwig Deubzer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2016-004180-39","Sponsor":"University Hospital, Saarland, Homburg","Studienbeginn":"2022-09-19 00:00:00","Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/201600418039"},{"Studiencode":"20017425","Studiencode_Anzeige":"20017425","Kurzbezeichnung":"MK-7684-005","Studientitel":"MK 7684-005","Status":"active","Phase":"Phase II","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Charité Comprehensive Cancer Center (CCCC)","PI":"Prof. Dr. Sebastian Ochsenreither; Prof. Dr. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017425"},{"Studiencode":"20015053","Studiencode_Anzeige":"20015053","Kurzbezeichnung":"nanoDx","Studientitel":"Methylation-based classification of brain tumors using nanopore sequencing (nanoDx): a prospective, multicentric evaluation","Status":"active","Phase":"Nicht zutreffend","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Neurologie mit Experimenteller Neurologie CCM","PI":"Philipp Euskirchen;  Philipp Euskirchen","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20015053"},{"Studiencode":"3001103","Studiencode_Anzeige":"3001103","Kurzbezeichnung":"TITAN2","Studientitel":"Tumorimmuntherapie assoziierte neurologische Nebenwirkungen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Neurologie mit Experimenteller Neurologie CCM","PI":"Dr. med. Samuel Knauß; Dr. med. Samuel Knauß","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001103"},{"Studiencode":"20018996","Studiencode_Anzeige":"20018996","Kurzbezeichnung":"HypoFocal-SBRT","Studientitel":"Bildgesteuerte fokale Dosiseskalation bei Patienten mit primärem Prostatakarzinom, die mit primärer externer hypofraktionierter stereotaktischer Strahlentherapie behandelt werden - eine prospektive, multizentrische, randomisierte Phase-III-Studie","Status":"active","Phase":"Phase III","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie","PI":"Priv.-Doz. Dr. med. Sebastian Zschaeck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Freiburg  (University of Freiburg)","Studienbeginn":"2025-06-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20018996"},{"Studiencode":"20006425","Studiencode_Anzeige":"20006425","Kurzbezeichnung":"MageA1-TCR","Studientitel":"MageA1-TCR Klin. Studie T-Zellrezeptor-Gentherapie","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Institut für Immunologie","PI":"antonio.pezzutto@charite.de;   antonio.pezzutto@charite.de","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20006425"},{"Studiencode":"3000764","Studiencode_Anzeige":"3000764","Kurzbezeichnung":"PRIME-Registerstudie","Studientitel":"Systematische Bewertung und Nachverfolgung aller Patienten mit fortgeschrittenen Tumorerkrankungen, die im Rahmen des Charité Präzisionsonkologieprogramms vorgestellt werden und für die eine molekulare Typisierung in Betracht gezogen wird.","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Dr. med. Damian Tobias Rieke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"Charité","Studienbeginn":"2016-01-01 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000764"},{"Studiencode":"20017475","Studiencode_Anzeige":"20017475","Kurzbezeichnung":"TK-SCR-01","Studientitel":"T-Knife TK-SCR-01","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017475"},{"Studiencode":"20245139003200","Studiencode_Anzeige":"20024095","Kurzbezeichnung":"VIDAR-1","Studientitel":"Protocol Title: Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCRModified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes","Status":"active","Phase":"Phase I/II","Organsystem":"Pankreas","Organsystem_Alias":"Pankreas","Molekulare Marker":"KRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-513900-32-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245139003200"},{"Studiencode":"20024205","Studiencode_Anzeige":"20024205","Kurzbezeichnung":"PAN-Lymphom-Register","Studientitel":"PAN-Lymphom-Register der GLA","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"Sonstiges","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line, 2nd line, 3rd line,","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Dr. med. Sophy Denker; Dr. med. Sophy Denker","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024205"},{"Studiencode":"202350629436","Studiencode_Anzeige":"20023983","Kurzbezeichnung":"eVOLVE D798EC00001","Studientitel":"eVOLVE D798EC00001","Status":"active","Phase":"Phase III","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":"PD-L1","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"PD Dr. med. Konrad Klinghammer; PD Dr. med. Konrad Klinghammer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-506294-36","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/202350629436"},{"Studiencode":"20225018694100","Studiencode_Anzeige":"20021990","Kurzbezeichnung":"HEM-iSMART","Studientitel":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)","Status":"active","Phase":"Phase I/II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL, Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"2nd line, 3rd line, Andere","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. Andrej Lissat; Dr. Andrej Lissat","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2021-003398-79","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225018694100"},{"Studiencode":"3001806","Studiencode_Anzeige":"3001806","Kurzbezeichnung":"ARISE","Studientitel":"Molekulare und funktionelle Charakterisierung von genetischen Aberrationen für die Immunantwort in hämatopoetischen Erkrankungen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"CD19","Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":";","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001806"},{"Studiencode":"20245128942900","Studiencode_Anzeige":"20017090","Kurzbezeichnung":"DKTK-PMO-1605","Studientitel":"DKTK PMO 1605","Status":"active","Phase":"Phase I","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"prostata","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Charité Comprehensive Cancer Center (CCCC)","PI":"Prof. Dr. Sebastian Ochsenreither; Prof. Dr. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2019-000238-20","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245128942900"},{"Studiencode":"3001742","Studiencode_Anzeige":"3001742","Kurzbezeichnung":"ARC-Registry","Studientitel":"Multicenter Analysis of Local Radiotherapy for CNS lymphoma – ARC-Registry","Status":"active","Phase":"Nicht zutreffend","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"ZNS-Lymphom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Dr. med. Alexander Hansch; Dr. med. Alexander Hansch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001742"},{"Studiencode":"20021255","Studiencode_Anzeige":"20021255","Kurzbezeichnung":"MOBY Studie","Studientitel":"Auswirkungen der Nutzung einer mobilen Schutzkapsel auf die Lebensqualität bei pädiatrischen Patienten mit schwerer Immunsuppression – prospektive, Single-Center Kohortenstudie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. Georg Seifert; Prof. Dr. Georg Seifert","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20021255"},{"Studiencode":"20021231","Studiencode_Anzeige":"20021231","Kurzbezeichnung":"VoraxazE","Studientitel":"A Prospective, Observational, Multi-country, Post-marketing Study onn the Safety and Efficacy of Voraxaze (Glucarpidase) in Subjects with Delayed Methotrexate Elimination or at Risk of Methotrexate Toxicity","Status":"active","Phase":"Phase IV","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Stefan Schwartz; Prof. Dr. Stefan Schwartz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20021231"},{"Studiencode":"20235087872900","Studiencode_Anzeige":"20023673","Kurzbezeichnung":"ADAPT TN III","Studientitel":"ADAPT TN III","Status":"active","Phase":"Phase II","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"Sonstiges;PD-L1;PD-1;BRCA2;BRCA1","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Neoadjuvant","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Brustzentrum der Charité CCM","PI":"Dr. med. Caroline Neeb; Dr. med. Caroline Neeb","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-508787-29-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235087872900"},{"Studiencode":"03567889","Studiencode_Anzeige":"20027494","Kurzbezeichnung":"PH-L19IL2TNF-01/18 Neodream","Studientitel":"An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Malignes Melanom","Therapiesetting":"Neoadjuvant","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Thomas Eigentler; Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT03567889","EudraCT-Nr":"2023-507119-36-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/03567889"},{"Studiencode":"20245157653400","Studiencode_Anzeige":"20025711","Kurzbezeichnung":"BNT327-03","Studientitel":"A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with firstline extensive-stage small-cell lung cancer","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":null,"Histologischer Typ":"Neuroendokrin (NET and NEC)","Therapiesetting":"Metastasiert","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin","PI":"PD Dr. med. Nikolaj Frost; PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-515765-34-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245157653400"},{"Studiencode":"07227402","Studiencode_Anzeige":"20026416","Kurzbezeichnung":"MK-6482-033","Studientitel":"A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy","Status":"active","Phase":"Phase III","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":"PD-L1, PD-1","Histologischer Typ":"RCC","Therapiesetting":"Rezidiv/Refraktär","Therapielinie":"2nd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Dr. Barbara Erber","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studienkoordination-uro@charite.de","Ansprechpartner_Telefon":"'+49 30 450615285","ClinTrials.gov identifier":"NCT07227402","EudraCT-Nr":"2024-517136-21","Sponsor":"Merck Sharp & Dohme Corp.","Studienbeginn":"2026-04-07 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07227402"},{"Studiencode":"20255224002400","Studiencode_Anzeige":"20027173","Kurzbezeichnung":"BMS CA224-0012","Studientitel":"BMS CA244-0012","Status":"active","Phase":"Phase II/III","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Urologie CCM","PI":"Prof. Dr. med. Maria De Santis; Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-522400-24","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255224002400"},{"Studiencode":"20245172473100","Studiencode_Anzeige":"20027959","Kurzbezeichnung":"GLORA-4","Studientitel":"A Global Multicenter, Double-Blind, Randomized, Registrational \nPhase 3 Study of Lisaftoclax (APG-2575) in Combination with \nAzacitidine (AZA) in Patients with Newly Diagnosed Higher Risk \nMyelodysplastic Syndrome (HR-MDS)","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":null,"Histologischer Typ":"MDS","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Dr. med. Kathrin Rieger; Dr. med. Kathrin Rieger","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-517247-31","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245172473100"},{"Studiencode":"20245131222700","Studiencode_Anzeige":"20025664","Kurzbezeichnung":"Daiichi-DS8201-724","Studientitel":"A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu ) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus\nTrastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer (DESTINY-Gastric05)","Status":"active","Phase":"Phase III","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":"HER2/neu","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Fortgeschritten","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Dr. med. Annika Kurreck; Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-513122-27-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245131222700"},{"Studiencode":"07227870","Studiencode_Anzeige":"20027134","Kurzbezeichnung":"PH-L19IL2TNFBCC-05/2","Studientitel":"A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally\nadvanced Basal Cell Carcinoma patients progressed on or intolerant to systemic\ntreatment","Status":"active","Phase":"Phase II","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Basalzellkarzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Thomas Eigentler; Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT07227870","EudraCT-Nr":"2025-523230-77-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07227870"},{"Studiencode":"20255232311900","Studiencode_Anzeige":"20027132","Kurzbezeichnung":"PH-L19IL2TNFSCC-06/2","Studientitel":"A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous\nSquamous Cell Carcinoma patients progressing on or intolerant to systemic treatment","Status":"active","Phase":"Phase II","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":null,"Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Prof. Dr. Thomas Eigentler; Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-523231-19-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255232311900"},{"Studiencode":"20245150231100","Studiencode_Anzeige":"20027171","Kurzbezeichnung":"PEAK-1","Studientitel":"Peak-1 Arcus","Status":"active","Phase":"Phase III","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":null,"Histologischer Typ":"RCC","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Urologie CCM","PI":"Prof. Dr. med. Maria De Santis; Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-515023-11-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245150231100"},{"Studiencode":"3001698","Studiencode_Anzeige":"3001698","Kurzbezeichnung":"PagRet","Studientitel":"Pagetoide Retikulose und ihre Differentialdiagnosen-eine multizentrische, retrospektive und nicht-interventionelle Studie zur Beschreibung der histologischen und klinischen Kriterien","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"CD3","Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Dr. med. Rose Moritz; Dr. med. Rose Moritz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001698"},{"Studiencode":"20025121","Studiencode_Anzeige":"20025121","Kurzbezeichnung":"PHOEBUS","Studientitel":"A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications","Status":"active","Phase":"Phase IIb","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"knochenmark","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. med. Olaf Penack; Prof. Dr. med. Olaf Penack","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20025121"},{"Studiencode":"20025373","Studiencode_Anzeige":"20025373","Kurzbezeichnung":"Her2 Main Study","Studientitel":"HER2 Main Study","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"HER2/neu","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Urologie CCM","PI":"Prof. Dr. med. Maria De Santis; Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20025373"},{"Studiencode":"20022671","Studiencode_Anzeige":"20022671","Kurzbezeichnung":"D419CR00035","Studientitel":"An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"Sonstiges","Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. Dominik Paul Modest; Prof. Dr. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20022671"},{"Studiencode":"20255235245300","Studiencode_Anzeige":"20027153","Kurzbezeichnung":"Pfizer C6461008","Studientitel":"Pfizer C6461008","Status":"active","Phase":"Phase I/II","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":null,"Histologischer Typ":"RCC","Therapiesetting":"Fortgeschritten","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Urologie CCM","PI":"Prof. Dr. med. Maria De Santis; Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-523524-53-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255235245300"},{"Studiencode":"05902169","Studiencode_Anzeige":"20024776","Kurzbezeichnung":"SONOBIRD","Studientitel":"A randomized, open-label, multicentric, two-arm pivotal trial of SonoCloud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma","Status":"active","Phase":"Phase III","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"Hirntumor","Therapiesetting":"Nicht zutreffend","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Neurochirurgie CCM","PI":"Dr. med. Martin Misch; Dr. med. Martin Misch","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05902169","EudraCT-Nr":"2023-505829-14","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05902169"},{"Studiencode":"20245172611600","Studiencode_Anzeige":"20026265","Kurzbezeichnung":"BNT326-01","Studientitel":"BNT326-01","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Charité Comprehensive Cancer Center (CCCC)","PI":"Prof. Dr. Sebastian Ochsenreither; Prof. Dr. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-517261-16-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245172611600"},{"Studiencode":"20027678","Studiencode_Anzeige":"20027678","Kurzbezeichnung":"BiliCan","Studientitel":"Biliary liquid biopsies for early cancer diagnosis in patients with indeterminate biliary strictures (BiliCan)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"Sonstiges","Histologischer Typ":"Gallengangskarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie (einschl. Arbeitsbereich Ernährungsmedizin) CBF","PI":"Dr. med. Christoph Treese; Dr. med. Christoph Treese","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20027678"},{"Studiencode":"20024736","Studiencode_Anzeige":"20024736","Kurzbezeichnung":"Happy Kraut Study","Studientitel":"Effects of Sauerkraut on seasonal allergies, on markers of inflammation and the gut microbiome in young adults.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Nasenhöhle und Nasennebenhöhlen","Organsystem_Alias":"nasenhöhle","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Gonza Balbina Ngoumou; Dr. med. Gonza Balbina Ngoumou","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20024736"},{"Studiencode":"20016922","Studiencode_Anzeige":"20016922","Kurzbezeichnung":"ART","Studientitel":"Potentiale der Mind-Body-Medizin zur Verbesserung der Stressregulation","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. Georg Seifert; Prof. Dr. Georg Seifert","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20016922"},{"Studiencode":"20023883","Studiencode_Anzeige":"20023883","Kurzbezeichnung":"JNJ-88549968","Studientitel":"A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Dr. med. Marie Luise Barbara Hütter-Krönke; Dr. med. Marie Luise Barbara Hütter-Krönke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20023883"},{"Studiencode":"20017991","Studiencode_Anzeige":"20017991","Kurzbezeichnung":"ESCORT-HU Extension","Studientitel":"ESCORT-HU-Erweiterung: Europäische Kohorte mit Sichelzellkrankheit – Hydroxyurea – Erweiterungsstudie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"PD Dr. med. Lena Oevermann; PD Dr. med. Lena Oevermann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20017991"},{"Studiencode":"3001514","Studiencode_Anzeige":"3001514","Kurzbezeichnung":"EWOG-SAA","Studientitel":"Registry of the European Working Group (EWOG) of Severe Aplastic Anemia (SAA) in children and adolescents","Status":"active","Phase":"Phase IV","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Aplastische Anämie","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend Stackelberg; Prof. Dr. med. Arend Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3001514"},{"Studiencode":"3000155","Studiencode_Anzeige":"3000155","Kurzbezeichnung":"TFR-PRO","Studientitel":"Retro-prospektive Beobachtungsstudie zum Progressionsrisiko bei Patienten mit chronischer myeloischer Leukämie in chronischer Phase, die für das Absetzen des Tyrosin kinase-Inhibitors in Frage kommen","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"CML","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. med. Philipp Coutre; Prof. Dr. med. Philipp Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3000155"},{"Studiencode":"20019074","Studiencode_Anzeige":"20019074","Kurzbezeichnung":"ITP-Register","Studientitel":"Multizentrisches nationales ITP-Register und begleitende Bioproben-Sammlung","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Dr. med. Marie Luise Barbara Hütter-Krönke; Dr. med. Marie Luise Barbara Hütter-Krönke","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20019074"},{"Studiencode":"20015428","Studiencode_Anzeige":"20015428","Kurzbezeichnung":"Register SCD","Studientitel":"Register Sichelzellkrankheit","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"PD Dr. med. Lena Oevermann; PD Dr. med. Lena Oevermann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20015428"},{"Studiencode":"20022187","Studiencode_Anzeige":"20022187","Kurzbezeichnung":"Ascany Register","Studientitel":"German prospective registry for patients with chronic myeloid leukemia (CML) previously treated with ≥2 TKIs switched to ASCiminib or ANY ATP-competitive TKI Kurzbezeichnung: ASCANY Registry","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK","PI":"Prof. Dr. med. Philipp Coutre; Prof. Dr. med. Philipp Coutre","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20022187"},{"Studiencode":"07213804","Studiencode_Anzeige":null,"Kurzbezeichnung":"ENGOT-ov97/J5E-MC-JZXB (FRAmework-01)","Studientitel":"A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer","Status":"active","Phase":"Phase III","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"BRCA1, BRCA2","Histologischer Typ":"Ovarialkarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Klinik für Gynäkologie","PI":"Prof. Dr. Elena Braicu","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gyn-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 664 408","ClinTrials.gov identifier":"NCT07213804","EudraCT-Nr":"2025-522255-25-00","Sponsor":"Eli Lilly and Company","Studienbeginn":"2026-06-25 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07213804"},{"Studiencode":"05999396","Studiencode_Anzeige":"20023234","Kurzbezeichnung":"CoReCC3 IIT","Studientitel":"First in Human Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT05999396","EudraCT-Nr":"2022-503084-15-00","Sponsor":"DKFZ","Studienbeginn":"2026-04-07 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/05999396"},{"Studiencode":"06026410","Studiencode_Anzeige":"20024327","Kurzbezeichnung":"KO-2806-001","Studientitel":"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors","Status":"active","Phase":"Phase I","Organsystem":"Harnorgane","Organsystem_Alias":"Harnorgane","Molekulare Marker":"KRAS, HRAS","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line","Standort":"CCM","Klinische Fachabteilung":"Charité Comprehensive Cancer Center","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06026410","EudraCT-Nr":"2024-513285-19-00","Sponsor":"Kura Oncology, Inc.","Studienbeginn":"2026-06-05 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06026410"},{"Studiencode":"06788990","Studiencode_Anzeige":"20026165","Kurzbezeichnung":"BCA101X301","Studientitel":"A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Status":"active","Phase":"Phase II","Organsystem":"Kopf-Hals","Organsystem_Alias":"Kopf-Hals","Molekulare Marker":"PD-L1","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Konrad Klinghammer","Ansprechpartner_Name":null,"Ansprechpartner_Email":"baerbel.hoellen@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06788990","EudraCT-Nr":"2024-519654-37-00","Sponsor":"Bicara Therapeutics Inc.","Studienbeginn":"2026-05-15 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06788990"},{"Studiencode":"06264180","Studiencode_Anzeige":"20025820","Kurzbezeichnung":"IGNYTE-3","Studientitel":"Randomized, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment","Status":"active","Phase":"Phase III","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF, PD-1","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":"NCT06264180","EudraCT-Nr":"2023-508612-29-00","Sponsor":"Replimune Inc.","Studienbeginn":"2026-04-27 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06264180"},{"Studiencode":"06793215","Studiencode_Anzeige":"20025085","Kurzbezeichnung":"Krascendo 2","Studientitel":"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","Status":"active","Phase":"Phase III","Organsystem":"Lunge und Bronchien","Organsystem_Alias":"Lunge und Bronchien","Molekulare Marker":"PD-L1, KRAS","Histologischer Typ":"NSCLC","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Klinik für Pneumologie","PI":"PD Dr. med. Nikolaj Frost","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studien-pneumologie@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 044","ClinTrials.gov identifier":"NCT06793215","EudraCT-Nr":"2024-518365-10-00","Sponsor":"Hoffmann-La Roche  (Hoffmann-La Roche)","Studienbeginn":"2026-04-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06793215"},{"Studiencode":"07176312","Studiencode_Anzeige":"20027013","Kurzbezeichnung":"ZANGEA","Studientitel":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","Status":"active","Phase":"Phase II","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":"PD-L1, HER2","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Priv.-Doz. Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":"inna.hoyer@charite.de","Ansprechpartner_Telefon":"'+49 30 450553844","ClinTrials.gov identifier":"NCT07176312","EudraCT-Nr":"2025-522718-22-00","Sponsor":"IKF Klinische Krebsforschung GmbH","Studienbeginn":"2026-04-17 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07176312"},{"Studiencode":"06330064","Studiencode_Anzeige":"20023676","Kurzbezeichnung":"Daiichi DS7300-203","Studientitel":"A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors","Status":"active","Phase":"Phase I/II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Metastasiert","Therapielinie":"2nd line, 3rd line, Andere","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Univ.-Prof. Dr. med. Sebastian Ochsenreither","Ansprechpartner_Name":null,"Ansprechpartner_Email":"ectu@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":"NCT06330064","EudraCT-Nr":"2023-509632-26-00","Sponsor":"Daiichi Sankyo Inc.","Studienbeginn":"2026-04-14 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06330064"},{"Studiencode":"20245151271100_2","Studiencode_Anzeige":"20024581","Kurzbezeichnung":"Zugspritze","Studientitel":"A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients","Status":"active","Phase":"Phase II","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Erstdiagnose","Therapielinie":"1st line","Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marco.kanter@charite.de","Ansprechpartner_Telefon":"'+49 30 450 630 074","ClinTrials.gov identifier":null,"EudraCT-Nr":"2020-003925-42","Sponsor":"LMU München  (LMU München)","Studienbeginn":"2026-01-06 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245151271100_2"},{"Studiencode":"05690048","Studiencode_Anzeige":"20023662","Kurzbezeichnung":"FLORA","Studientitel":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab","Status":"active","Phase":"Phase II","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"2nd line","Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marco.kanter@charite.de","Ansprechpartner_Telefon":"'+49 30 450 630 074","ClinTrials.gov identifier":"NCT05690048","EudraCT-Nr":"2023-506887-15-00","Sponsor":"University of Heidelberg","Studienbeginn":"2026-03-12 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/05690048"},{"Studiencode":"07213674","Studiencode_Anzeige":"20026452","Kurzbezeichnung":"Amgen 20230239","Studientitel":"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","Status":"active","Phase":"Phase III","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"Männliche Genitalorgane","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"3rd line","Standort":"CCM","Klinische Fachabteilung":"Klinik für Urologie","PI":"Prof. Dr. med. Maria De Santis","Ansprechpartner_Name":null,"Ansprechpartner_Email":"studienkoordination-uro@charite.de","Ansprechpartner_Telefon":"'+49 30 450 615 297","ClinTrials.gov identifier":"NCT07213674","EudraCT-Nr":"2025-520555-89","Sponsor":"Amgen GmbH  (Amgen GmbH)","Studienbeginn":"2026-01-27 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07213674"},{"Studiencode":"20245173301800_2","Studiencode_Anzeige":"20025439","Kurzbezeichnung":"TRITICC-2","Studientitel":"Wirksamkeit und Sicherheit von TRIFLURIDIN/TIPIRACIL in Kombination mit NANOLIPOSOMALEM IRINOTECAN als Zweitlinientherapie bei Patienten mit Cholangiokarzinom","Status":"active","Phase":"Phase II","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"2nd line","Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":"marco.kanter@charite.de","Ansprechpartner_Telefon":"'+49 30 450 630 074","ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-517330-18","Sponsor":"University of Duesseldorf","Studienbeginn":"2026-01-30 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245173301800_2"},{"Studiencode":"07221149","Studiencode_Anzeige":"20026866","Kurzbezeichnung":"CA266-0004 ROSETTA","Studientitel":"A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","Status":"active","Phase":"Phase II/III","Organsystem":"Oberer GI-Trakt","Organsystem_Alias":"Oberer GI-Trakt","Molekulare Marker":"HER2","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Priv.-Doz. Dr. med. Annika Kurreck","Ansprechpartner_Name":null,"Ansprechpartner_Email":"conko-studien@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 834","ClinTrials.gov identifier":"NCT07221149","EudraCT-Nr":"2025-523263-37","Sponsor":"Bristol-Myers Squibb","Studienbeginn":"2026-04-24 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07221149"},{"Studiencode":"06252649","Studiencode_Anzeige":"20023416","Kurzbezeichnung":"CodeBreaK 301","Studientitel":"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"kolon","Molekulare Marker":"KRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CVK","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. med. Dominik Paul Modest","Ansprechpartner_Name":null,"Ansprechpartner_Email":"inna.hoyer@charite.de","Ansprechpartner_Telefon":"'+49 30 450553844","ClinTrials.gov identifier":"NCT06252649","EudraCT-Nr":"2022-502352-31-00","Sponsor":"Amgen GmbH  (Amgen GmbH)","Studienbeginn":"2026-03-12 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06252649"},{"Studiencode":"07365930","Studiencode_Anzeige":"20027410","Kurzbezeichnung":"NISTIPS","Studientitel":"Non-Interventional Study on the Benefits of Transjugular Intrahepatic Portosystemic Shunting in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab in First-Line Therapy","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":null,"Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie","PI":"PD Dr. Severin Daum","Ansprechpartner_Name":null,"Ansprechpartner_Email":"gastro-ced-studie@charite.de","Ansprechpartner_Telefon":"'+49 30 8445 4708","ClinTrials.gov identifier":"NCT07365930","EudraCT-Nr":null,"Sponsor":"IKF Klinische Krebsforschung GmbH","Studienbeginn":"2026-06-23 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07365930"},{"Studiencode":"20027312_2","Studiencode_Anzeige":"20027312","Kurzbezeichnung":"PRISMA NCT","Studientitel":"Eine randomisierte Pilotstudie der Phase II zu sozialen Rezepten und Microlearning zur Verbesserung der Versorgung von Krebspatient*innen und ihren Bezugspersonen","Status":"active","Phase":"Phase II","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Susanne Malaika Rittig","Ansprechpartner_Name":null,"Ansprechpartner_Email":"baerbel.hoellen@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 484","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Regensburg","Studienbeginn":"2026-07-28 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20027312_2"},{"Studiencode":"06856837","Studiencode_Anzeige":"20025015","Kurzbezeichnung":"AIO-KRK-0324 (QUINTIS)","Studientitel":"A Randomized Phase II Trial Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","Status":"active","Phase":"Phase II","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"BRAF, KRAS, NRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"PD Dr. med. Arndt Stahler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"haemaonko-studienccm@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 828","ClinTrials.gov identifier":"NCT06856837","EudraCT-Nr":"2024-519929-38-00","Sponsor":"IKF Klinische Krebsforschung GmbH","Studienbeginn":"2026-04-10 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06856837"},{"Studiencode":"06467357","Studiencode_Anzeige":"20025163","Kurzbezeichnung":"DESTINY-BTC01","Studientitel":"DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer","Status":"active","Phase":"Phase III","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"PD-L1, HER2","Histologischer Typ":"Gallengangskarzinom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. Annabel Alig","Ansprechpartner_Name":null,"Ansprechpartner_Email":"haemaonko-studienccm@charite.de","Ansprechpartner_Telefon":"'+49 30 450 553 828","ClinTrials.gov identifier":"NCT06467357","EudraCT-Nr":"2023-508057-19-00","Sponsor":"AstraZeneca","Studienbeginn":"2026-05-20 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06467357"},{"Studiencode":"07555938","Studiencode_Anzeige":null,"Kurzbezeichnung":"CO46096 (CEVOLUTION)","Studientitel":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":"CD38","Histologischer Typ":"Mult. Myelom (MM)","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Dr. med. David Böckle","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT07555938","EudraCT-Nr":"2025-524028-23-00","Sponsor":"Hoffmann-La Roche  (Hoffmann-La Roche)","Studienbeginn":"2026-08-13 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07555938"},{"Studiencode":"07015242","Studiencode_Anzeige":null,"Kurzbezeichnung":"CA082-1215 (CAROLYN)","Studientitel":"The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients","Status":"active","Phase":"Phase II","Organsystem":"ZNS","Organsystem_Alias":"ZNS","Molekulare Marker":null,"Histologischer Typ":"ZNS-Lymphom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Björn Chapuy","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT07015242","EudraCT-Nr":"2025-521144-38","Sponsor":"Bristol-Myers Squibb","Studienbeginn":"2026-06-29 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/07015242"},{"Studiencode":"06045195","Studiencode_Anzeige":null,"Kurzbezeichnung":"Pembro-FLASH","Studientitel":"Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Hodgkin Lymphom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Stephan Mathas","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":"NCT06045195","EudraCT-Nr":null,"Sponsor":"University of Cologne","Studienbeginn":"2026-06-16 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/06045195"},{"Studiencode":"20027783_2","Studiencode_Anzeige":"20027783","Kurzbezeichnung":"PEF-Adjuvant","Studientitel":"Partizipative Entscheidungsfindung (PEF) zur adjuvanten Systemtherapie beim Melanom – multizentrische, prospektive, clusterrandomisierte Implementierungsstudie im Stepped-Wedge-Design","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Haut","Organsystem_Alias":"Haut","Molekulare Marker":"BRAF","Histologischer Typ":"Malignes Melanom","Therapiesetting":"Metastasiert, Erstdiagnose","Therapielinie":"Keine","Standort":"CCM","Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie","PI":"Prof. Dr. Thomas Eigentler","Ansprechpartner_Name":null,"Ansprechpartner_Email":"nurcan.uzun@charite.de","Ansprechpartner_Telefon":"'+49 30 450 518448","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":"University of Heidelberg","Studienbeginn":"2026-04-08 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20027783_2"},{"Studiencode":"20260914C1974","Studiencode_Anzeige":null,"Kurzbezeichnung":"RD006583","Studientitel":"Probensammlung und Bestimmung der Probenstabilität einzelner Analyten für cobas® Mass Spec","Status":"active","Phase":null,"Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":null,"Standort":"CBF","Klinische Fachabteilung":"Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie","PI":"Prof. Dr. Stefan Schwartz","Ansprechpartner_Name":null,"Ansprechpartner_Email":"anja.ullrich-noss@charite.de","Ansprechpartner_Telefon":"'+49 30 450 513 512","ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":"2026-05-19 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20260914C1974"},{"Studiencode":"20235048801800","Studiencode_Anzeige":"20019067","Kurzbezeichnung":"CRISP","Studientitel":"A phase1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Karzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line, 2nd line, 3rd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Anne Thorwarth; Dr. med. Anne Thorwarth","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2015-005437-53","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235048801800"},{"Studiencode":"20235098101300","Studiencode_Anzeige":"20019802","Kurzbezeichnung":"B1931036","Studientitel":"A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA","Status":"active","Phase":"Phase II","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"Lymphatisches und blutbildendes System","Molekulare Marker":"CD19","Histologischer Typ":"ALL","Therapiesetting":"Neoadjuvant","Therapielinie":"2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend Stackelberg; Prof. Dr. med. Arend Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2022-000186-40","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235098101300"},{"Studiencode":"20245105794000","Studiencode_Anzeige":"20027745","Kurzbezeichnung":"FaR-Rms","Studientitel":"FaR-RMS An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma","Status":"active","Phase":"Phase III","Organsystem":"Sonstiges","Organsystem_Alias":null,"Molekulare Marker":"Sonstiges","Histologischer Typ":"Sonstiges","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line, 2nd line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Anne Thorwarth; Dr. med. Anne Thorwarth","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2018-000515-24","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245105794000"},{"Studiencode":"20235071784100","Studiencode_Anzeige":"20023360","Kurzbezeichnung":"MSD MK9999-01A","Studientitel":"LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors","Status":"active","Phase":"Phase I/II","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":"Sonstiges","Histologischer Typ":"Leukämien/Lymphome, Ewing-Sarkom, Neuroblastom","Therapiesetting":"Nicht zutreffend","Therapielinie":"2nd line, 3rd line, Andere","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Anne Thorwarth; Dr. med. Anne Thorwarth","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-507178-41","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235071784100"},{"Studiencode":"20255235211800","Studiencode_Anzeige":"20027118","Kurzbezeichnung":"C6461003 Pfizer","Studientitel":"AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAIVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER","Status":"active","Phase":"Phase III","Organsystem":"Unterer GI-Trakt","Organsystem_Alias":"Unterer GI-Trakt","Molekulare Marker":"KRAS;NRAS","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CCM","PI":"PD Dr. med. Arndt Stahler; PD Dr. med. Arndt Stahler","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-523521-18-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255235211800"},{"Studiencode":"20245182108100","Studiencode_Anzeige":"20026023","Kurzbezeichnung":"ARTEMIDE-HCC01","Studientitel":"Evaluation of PD-L1 Expression Levels in Hepatocellular Carcinoma Specimens from Phase III Study D7029C00001","Status":"active","Phase":"Phase III","Organsystem":"Leber; Gallenblase und Gallenwege","Organsystem_Alias":"Leber; Gallenblase und Gallenwege","Molekulare Marker":"Sonstiges;Nicht zutreffend","Histologischer Typ":"Hepatozelluläres Karzinom (HCC)","Therapiesetting":"Fortgeschritten","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hepatologie und Gastroenterologie CVK","PI":"Dr. med. univ. Raphael Mohr; Dr. med. univ. Raphael Mohr","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-518210-81-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245182108100"},{"Studiencode":"03590171","Studiencode_Anzeige":"20017317","Kurzbezeichnung":"IntReALL2010/ALLREZ","Studientitel":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010, International Study for Treatment of High Risk Childhood Relapsed ALL 2010, ALL-REZ BFM Register","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend Stackelberg; Prof. Dr. med. Arend Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT03590171","EudraCT-Nr":"2012-000810-12","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/03590171"},{"Studiencode":"20235104291400","Studiencode_Anzeige":"20028214","Kurzbezeichnung":"BI 1479-0009","Studientitel":"BI1479-0009","Status":"active","Phase":"Phase I","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"HER2/neu","Histologischer Typ":"Adenokarzinom","Therapiesetting":"Metastasiert","Therapielinie":"3rd line","Standort":null,"Klinische Fachabteilung":"Charité Comprehensive Cancer Center (CCCC)","PI":"PD Dr. med. Damian Tobias Rieke Lang; PD Dr. med. Damian Tobias Rieke Lang","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-510429-14-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235104291400"},{"Studiencode":"20255244684000","Studiencode_Anzeige":"20027222","Kurzbezeichnung":"CURE GvHD","Studientitel":"CURE GvHD","Status":"active","Phase":"Phase I","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CBF","PI":"Prof. Dr. Antonia Busse; Prof. Dr. Antonia Busse","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-524468-40-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255244684000"},{"Studiencode":"20225025033000","Studiencode_Anzeige":"20023384","Kurzbezeichnung":"Interfant21","Studientitel":"Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"ALL","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Prof. Dr. med. Arend Stackelberg; Prof. Dr. med. Arend Stackelberg","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2021-000213-16","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20225025033000"},{"Studiencode":"20245178123100","Studiencode_Anzeige":"20025207","Kurzbezeichnung":"Altuvoct 005","Studientitel":"A low-interventional study to evaluate long-term effectiveness of real-world treatment with efanesoctocog alfa on joint-health in people with haemophilia A","Status":"active","Phase":"Phase IV","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Susanne Holzhauer; Dr. med. Susanne Holzhauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-517812-31-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245178123100"},{"Studiencode":"20245159261000","Studiencode_Anzeige":"20025451","Kurzbezeichnung":"PNH Iptacopan","Studientitel":"An open-label, single-arm, multicenter, phase 3 study to assess pharmacokinetics, safety and tolerability of iptacopan in pediatric PNH patients 2 to <18 years of age","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Susanne Holzhauer; Dr. med. Susanne Holzhauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2024-515926-10","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20245159261000"},{"Studiencode":"20235041466000","Studiencode_Anzeige":"20025922","Kurzbezeichnung":"EPIK L1 Alpelisib","Studientitel":"A two-stage double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation\n\nCBYL719P12201","Status":"active","Phase":"Phase II/III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Susanne Holzhauer; Dr. med. Susanne Holzhauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2023-504146-60-00","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20235041466000"},{"Studiencode":"20255210552300","Studiencode_Anzeige":"20027071","Kurzbezeichnung":"ARGX-113-2409 ITP","Studientitel":"A Multicenter, Randomized, Double-Blinded, Parallel-Arm,\nPlacebo-Controlled, Pharmacokinetic and Pharmacodynamic Study\nFollowed by an Open-Label Arm to Evaluate Efgartigimod IV in\nPediatric Participants From 12 Years to Less Than 18 Years of Age\nWith Chronic ITP","Status":"active","Phase":"Phase II/III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"blutbildendes system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Susanne Holzhauer; Dr. med. Susanne Holzhauer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2025-521055-23","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20255210552300"},{"Studiencode":"202100647732","Studiencode_Anzeige":"20019065","Kurzbezeichnung":"NPC-Nivo","Studientitel":"Nivolumab in Kombination mit Cisplatin und 5-Fluorouracil als Induktionstherapie bei Kindern, Jugendlichen und jungen Erwachsenen mit EBV-assoziiertem Nasopharynxkarzinom","Status":"active","Phase":"Phase II","Organsystem":"Pharynx","Organsystem_Alias":"pharynx","Molekulare Marker":"Sonstiges","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. med. Anne Thorwarth; Dr. med. Anne Thorwarth","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":"2021-006477-32","Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/202100647732"},{"Studiencode":"3002073","Studiencode_Anzeige":"3002073","Kurzbezeichnung":"Image-N CTCL","Studientitel":"Bildgebungsgestützte Evaluation der Lymphknotenbeteiligung bei Patienten mit kutanen Lymphomen (CTCL)","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"Organübergreifend","Molekulare Marker":"CD3","Histologischer Typ":"Non-Hodgkin Lymphom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Dermatologie, Venerologie und Allergologie CCM","PI":"Dr. med. Rose Moritz; Dr. med. Rose Moritz","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3002073"},{"Studiencode":"3002102","Studiencode_Anzeige":"3002102","Kurzbezeichnung":"PREKOVER FU","Studientitel":"Follow-Up Evaluation der Frailty bei PatientInnen mit Kopf-Hals Tumoren nach kurativ intendierter Therapie","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Kopf-Hals","Organsystem_Alias":"kopf-hals","Molekulare Marker":"HPV16","Histologischer Typ":"Plattenepithelkarzinom","Therapiesetting":"Nicht zutreffend","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Radioonkologie und Strahlentherapie CVK","PI":"Prof. Dr. Franziska Hausmann; Prof. Dr. Franziska Hausmann","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3002102"},{"Studiencode":"20028668","Studiencode_Anzeige":"20028668","Kurzbezeichnung":"NAVIGATORR","Studientitel":"NAVIGATORR\nprospective, monocentricmulticentric, proof-of-concept trial","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Organübergreifend","Organsystem_Alias":"organübergreifend","Molekulare Marker":null,"Histologischer Typ":"Adenokarzinom, Plattenepithelkarzinom","Therapiesetting":"Adjuvant","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Mund-, Kiefer- und Gesichtschirurgie CVK / CBF","PI":"Prof. Dr. Dr. Max Heiland; Prof. Dr. Dr. Max Heiland","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/20028668"},{"Studiencode":"20027948","Studiencode_Anzeige":"20027948","Kurzbezeichnung":"BNGO Protokoll13902","Studientitel":"\"Real-world Analyse von Patienten-, Krankheits- und Therapiemerkmalen in Verbindung mit der Entscheidungsfindung und Therapieadhärenz bezüglich adjuvanter endokriner Therapie bei Patientinnen mit frühem HR+ HER2- Mammakarzinom mit hohem Rezidivrisiko\"","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":"ER+","Histologischer Typ":"Mammakarzinom","Therapiesetting":"Adjuvant","Therapielinie":"Keine","Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Brustzentrum der Charité CCM","PI":"Prof. Dr. Jens-Uwe Blohmer; Prof. Dr. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20027948"},{"Studiencode":"3002116","Studiencode_Anzeige":"3002116","Kurzbezeichnung":"LBL 2018","Studientitel":"LBL 2018\nInternational cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma","Status":"active","Phase":"Phase III","Organsystem":"Lymphatisches und blutbildendes System","Organsystem_Alias":"lymphatisches system","Molekulare Marker":null,"Histologischer Typ":"Leukämien/Lymphome","Therapiesetting":"Nicht zutreffend","Therapielinie":"1st line","Standort":null,"Klinische Fachabteilung":"Klinik für Pädiatrie m.S. Onkologie und Hämatologie","PI":"Dr. Andrej Lissat; Dr. Andrej Lissat","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"YES","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/3002116"},{"Studiencode":"20018718","Studiencode_Anzeige":"20018718","Kurzbezeichnung":"PRO B","Studientitel":"PRO B","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Männliche Genitalorgane","Organsystem_Alias":"prostata","Molekulare Marker":null,"Histologischer Typ":"Karzinom","Therapiesetting":null,"Therapielinie":null,"Standort":null,"Klinische Fachabteilung":"Klinik für Gynäkologie mit Brustzentrum der Charité CCM","PI":"Dr. med. Therese Pross; Dr. med. Therese Pross","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":null,"EudraCT-Nr":null,"Sponsor":null,"Studienbeginn":null,"Studienende":null,"Pediatric Study":"NO","NCT_Studie":"nein","Dashboard_Link":"/#/studieninfo/20018718"},{"Studiencode":"05906407","Studiencode_Anzeige":"20022024","Kurzbezeichnung":"CATCH/ COGNITION","Studientitel":"Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials: early high-risk breast carcinoma.","Status":"active","Phase":"Nicht zutreffend","Organsystem":"Brust","Organsystem_Alias":"Brust","Molekulare Marker":null,"Histologischer Typ":"Mammakarzinom","Therapiesetting":null,"Therapielinie":null,"Standort":"CCM","Klinische Fachabteilung":"Brustzentrum","PI":"Prof. Dr. Jens-Uwe Blohmer; Prof. Dr. Jens-Uwe Blohmer","Ansprechpartner_Name":null,"Ansprechpartner_Email":null,"Ansprechpartner_Telefon":null,"ClinTrials.gov identifier":"NCT05906407","EudraCT-Nr":null,"Sponsor":"DKFZ","Studienbeginn":"2023-12-20 00:00:00","Studienende":null,"Pediatric Study":"NO","NCT_Studie":"ja","Dashboard_Link":"/#/studieninfo/05906407"}]